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FDA has approved several cell-based therapeutics and hundreds of cell therapy
clinical trials are ongoing. Cells will be a significant type of medicine after small molecule
and protein drugs. However, several obstacles need to be addressed to achieve the
widespread use of cellular therapeutics. The first challenge is the low efficacy of cell
transplantation due to low retention, survival, integration, and function of cells in vivo. The
second challenge is producing a massive number of cells for clinical treatment with costeffectively and reproducibly technologies.
In this thesis, we proposed and investigated two approaches to address these
challenges. To begin with, we engineered two novel biomaterials to deliver cells to enhance
their in vivo retention and function. The first biomaterial is a recombinant fibrin matrix
which significantly improved cell delivery efficiency and safety. The second biomaterial
is a novel γγ’F1:pFN complex fibrin matrix, which enhanced cell culture and improved
wound healing. In the second approach, we engineered injectable, microscale, 3D tissues
to address the challenges. Brown adipose microtissues were prepared and injected to
alleviate obesity and associated type 2 diabetes mellitus(T2DM). In addition, we showed a
novel, scalable and cell-friendly cell culture technology (AlgTubes) for scalable

microtissue manufacturing. Animal cells were used for preliminary study and can be used
for food science to produce cultured meat. This technology has the potential to produce
any cell therapy-related cell types in the future. Finally, we also systematically proposed
engineering a physiologically relevant microenvironment for large-scale therapeutic cell
and microtissue production.
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CHAPTER 1.

INTRODUCTION

Overview
FDA has approved several cell-based therapeutics and hundreds of cell therapy
clinical trials are on-going1–4. The clinical outcome for treating many diseases are
exciting5–8. There is no doubt that cells will be a significant type of medicine after small
molecule and protein drugs9. However, several obstacles need to be addressed to achieve
the widespread use of cellular therapeutics

4,10

. The first challenge is the low retention,

survival, integration, and function of cells in vivo following transplantation. For instance,
only ~6% of transplanted dopaminergic (DA) neurons and ~1% of injected cardiomyocytes
survived in rodent models several months after transplantation11,12. Only a portion of cells
stays at the injection or lesion site. The lesion sites, which typically contain a high
concentration of inflammatory cells and factors and a low concentration of O2, nutrients,
and growth factors due to the absence of vascular structures, are very hostile to the
transplanted cells. The disruption of cell signaling, cell-cell, and cell-matrix interactions
during cell preparation13 before transplantation (termed anoikis) and acute cell apoptosis
during the injection14 also contribute to the low survival rate.
The second challenge is to produce a large number of cells15. For example, ~105
surviving DA neurons, ~109 cardiomyocytes, or ~109 β-cells are required to treat a patient
with Parkinson’s disease (PD), myocardial infarction (MI), or type I diabetes,
respectively15. Likewise, ~1010 hepatocytes or cardiomyocytes would be required for an
artificial human liver or heart, respectively16; a similar number of cells are needed to screen
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a library of a million compounds at once17,18. Considering the low survival of transplanted
cells in vivo, the large patient populations with degenerative diseases (over 1 million people
with PD, 1-2.5 million with type I diabetes, and ~8 million with MI in the US alone19), a
massive number of cells are needed.
In this thesis, we proposed and investigated two approaches to address these
challenges. The first approach used novel biomaterials to deliver cells to enhance their in
vivo retention and function. Research has shown that a biomaterial scaffold can
significantly improve the retention of cells, maintain high viability, keep cell phenotype
and provide cells a 3D microenvironment to grow and interact10,20. In this thesis, we
investigated two novel biomaterials for cell delivery and disease treatment. The first
biomaterial is a recombinant fibrin matrix which significantly improved cell delivery
efficiency and safety. The results are presented in chapter 2. The second biomaterial is a
novel γγ’F1:pFN complex fibrin matrix, which enhanced cell culture and improved wound
healing. The results are shown in chapter 3.
The second approach to address the challenges is using injectable, microscale,
3D tissues. Microtissues contain not only cells but also their native ECMs, cell-cell contacts,
cell-matrix interactions, 3D and vascular structures that can prevent cells from anoikis and
acute apoptosis during the transplantation21, promoting cell survival, integration,
maturation, and function in vivo22,23.

Besides these advantages over stem cells,

microtissues also have advantages over large tissues made via the conventional tissue
engineering approaches. They are injectable, so open surgery is not required for the
transplantation, which is extremely important for treating diseases in organs with
sophisticated structures (e.g., the brain). In addition, they can be produced on a large scale
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via GMP compliant bioreactors, giving them the potential for treating large populations of
patients. In chapter 4, we prepared and showed that brown adipose microtissues could
alleviate obesity and its associated type 2 diabetes mellitus(T2DM). In chapter 5, a novel,
scalable and cell-friendly technology (AlgTubes) anchored with RGD for microtissue
manufacturing was developed. Animal cells were used for preliminary study and can be
used for food science to produce cultured meat. This technology has the potential to
produce any cell therapy-related cell types in the future. In the last chapter (chapter 6), we
systematically proposed engineering a physiologically relevant microenvironment for
large-scale therapeutic cell and microtissue production.
Summaries of Chapters
Chapter 2: A recombinant fibrin matrix made with recombinant human fibrinogen,
recombinant human thrombin, and recombinant human factor XIII was used to culture and
deliver mesenchymal stem cells (MSCs). The fibrin matrix could significantly enhance the
retention of the delivered hMSCs. These recombinant proteins considerably reduce the cost
and risk of human pathogen transmission compared to the current plasma-derived fibrin
matrix.
Chapter 3: We synthesized a novel fibrin matrix exclusively from a 1:1 (molar ratio)
complex of γγ’F1 and pFN in the presence of highly active thrombin and recombinant
Factor XIII (rFXIIIa). In this matrix, the fibrin nanofibers were decorated with pFN
nanoclusters (termed γγ’F1:pFN fibrin). The γγ’F1:pFN fibrin enhanced the adhesion and
proliferation of primary human umbilical vein endothelium cells (HUVECs). HUVECs in
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the 3D γγ’F1:pFN fibrin exhibited a starkly enhanced vascular morphogenesis. Mouse
dermal wounds sealed by γγ’F1:pFN fibrin showed accelerated and improved healing,
suggesting that a 3D pFN presentation on a fibrin matrix promotes wound healing.
Chapter 4: We Engineered 3D brown adipose microtissues as anti-obesity
(OB)/type 2 diabetes (T2DM) therapeutics. They have considerable advantages over
dissociated brown adipocytes (BAs) for future clinical applications in product scalability,
storage, purity, quality, and in vivo safety, dosage, survival, integration, and efficacy. 3D
BA microtissues could be fabricated at large scales, cryopreserved for the long term, and
delivered via injection. BAs in the microtissues had higher purity and higher UCP-1 protein
expression than BAs prepared via 2D culture. In addition, 3D BA microtissues had good
in vivo survival and tissue integration and had no uncontrolled tissue overgrowth.
Furthermore, they showed good efficacy in preventing OB and T2DM with a very low
dosage compared to literature studies.
Chapter 5: We engineered an alginate hydrogel tube cell culture system to provide
adhesion for large-scale microtissue fabrication. We showed both mouse and quail
myoblasts could be efficiently expanded and differentiated in the system. The yields were
between 1x to 2x108 cells/mL hydrogel tubes. Myotubes were aligned along the hydrogel
tubes. When the hydrogel shell is dissolved with EDTA, these cell micro-fibers could be
used as building blocks to fabricate large volume meat.
Chapter 6: Cells will be a significant type of medicine. To achieve the full potential
of cellular therapeutics, we must be able to cost-effectively and reproducibly manufacture

5

cells at large scales and with high quality. Currently, the robust and cost-effective culture
of high-quality allogeneic or autologous cells on large scales is still very challenging.
Academia and industry focus on developing modular, disposable, and closed bioreactors,
automating the cell culture, integrating process analysis and control, and artificial
intelligence. We propose that the cell culture microenvironment impacts the cell culture
outcome and the critical need of creating a cell-friendly microenvironment during cell
manufacturing.
Future Research:
Based on the technologies and results from this dissertation, the following research
questions/topics can be conducted in the future:
1) The long-term effect of the recombinant fibrin matrix on cell survival, integration, and
function should be investigated. It will also be valuable to use clinic-relevant disease
models such as myocardial infarction and stroke to test the capability of the matrix to
retain the cells at the injection sites. The system should also be tested on other
therapeutic cell types such as stem cell-derived cardiomyocytes and neurons.
2) Novel γγ’F1:pFN complex should be tested to deliver cells and proteins. Can it improve
cell retention and survival in vivo? And is it better than the recombinant fibrin matrix
considering its sophistic nanostructure?
3) Can we incorporate endothelial cells to make vascularized BA microtissues? Can we
use human pluripotent stem cells as the source to make BA microtissue?
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4) Can we produce the BA microtissue at a large scale using the AlgTube cell culture
system?
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CHAPTER 2.

A TOTALLY RECOMBINANT FIBRIN MATRIX FOR

MESENCHYMAL STEM CELL CULTURE AND DELIVERY
Introduction
Human mesenchymal stem cells (MSCs) can be differentiated into a variety of
cells1–3 such as myoblasts4, osteoblasts5,6, chondroblasts7, and adipocytes8. They also
secrete a panel of factors that can modulate many biological processes including
inflammation and angiogenesis9. Consequently, they have been widely studied for
engineering tissues10,11 and treating diseases both in laboratories12,13, clinical trials14,15, and
clinics16,17 with encouraging results. For instance, transplanting MSCs enhanced bone
tissue repair18,19, promoted angiogenesis in the myocardial ischemic area20,21, improved
cardiac performance after myocardial infarction16,20,22, and reduced inflammation and
improved brain functions in a variety of neurological diseases23–25.
A significant challenge with using MSCs to treat diseases is that only a small
numbers of the systematically injected cells can home to the diseased sites21,26,27. A
solution to this challenge is to locally inject cells to the diseased sites. However, the
percentage of the injected cells that can stay at the injection site is still low. Researches
have shown injecting the cells with a biomaterial matrix can significantly enhance the
retention of cells at the injection site28–31. Both natural and synthetic biomaterial such as
collagen, hyaluronic acid, and polyethylene glycol hydrogels have been investigated for
this purpose28–31. Among the many biomaterials, fibrin is of particular interest due to its
biocompatibility and biodegradation32–34. In addition, it has been used in the clinic as a
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hemostatic material for a long time35. Fibrinogen (FI) is a linear, hexameric, 340 kDa
glycoprotein having 2 alpha, 2 beta and 2 gamma chains. Activated thrombin (FIIa) rapidly
polymerizes fibrinogen to form an insoluble hydrogel that is held together by electrostatic
and other noncovalent forces. Activated factor XIII (FXIIIa) can further crosslink this
hydrogel matrix using covalent bonds to make it more stable36. Fibrin matrices have been
widely used for culturing37,38 and delivering MSCs34,39.
The currently used fibrinogen is purified from human plasma. The shortcomings of
plasma derived fibrinogen include the high cost and potential of human pathogen
transmission40,41. To address the problem, we previously made transgenic cows to produce
recombinant human fibrinogen (rFI) in milk42. We have shown recombinant human
fibrinogen and plasma fibrinogen have comparable clotting speed, strength and function in
a swine liver trauma model43. In these studies, we also used activated recombinant human
factor XIII (rFXIIIa) and recombinant human thrombin (rFII) to polymerize the fibrinogen,
resulting in fibrin matrices made with entirely recombinant proteins43. These recombinant
proteins significantly reduce the cost and risk of human pathogen transmission. In this
study, we aim to explore if these totally recombinant fibrin matrices can be used to culture
and deliver MSCs. We first systematically studied the relationship between the matrix
formulation, the nanostructure and the behaviors of cells in the matrix. We then used an
optimized matrix to deliver MSCs to NOD-SCID mice. We found the matrix could
significantly enhance the retention of the delivered hMSCs.
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Materials and methods
Materials
Recombinant fibrinogen (rFI) was produced, characterized and purified as
previously described42,43. Briefly, the DNA sequences of human α, β, γ chains of fibrinogen
were inserted into the cow genome by the method of nuclear transfer. The fibrinogen was
produced in the milk of transgenic cows and purified through multiple precipitations and
chromatography42,43. Activated recombinant human factor XIII (rFXIIIa) was produced in
Pichia pastoris using published protocols42,44. Recombinant human thrombin (rFIIa) was
purchased from ZymoGenetics (Seattle, WA).
Cell culture
Mouse bone marrow mesenchymal stem cells (D1 cells, CRL12424) were
purchased from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin at 37 °C and 5% CO2. Primary human bone marrow
mesenchymal stem cells were purchased from Lonza and culture in MesenCult™ MSC
Basal Medium (Human) supplemented with MesenCult™ MSC Stimulatory Supplement
(Human) and 1% penicillin/streptomycin. Cells were passaged every 5 days with 0.25%
trypsin.
Fibrin matrix preparation
Recombinant fibrin matrices were prepared in Ringer’s solution (155 mM NaCl, 5
mM KCl, 2 mM CaCl2 and 1 mM MgCl2, pH=7.4) with different final concentrations of
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rFI, rFXIIIa, and rFII as described in the text. The protein mixtures were incubated at 37 °C
for 15 minutes in a cell culture incubator to form the fibrin matrices.
3D cell culture
100 µl fibrin matrix with 3 x 104 cells was made in one well of the 96-well plate.
200 µl cell culture medium was added on the top of the fibrin matrix in each well. At
various time points, cell morphologies were imaged with the phase-contrast microscope.
On day 2 and 4, the medium was removed and 100 µl fresh medium and 10 µl Alamar blue
reagent were added and incubated for 3 hours. 100 µl medium from each well was collected
to measure the fluorescence, which was calibrated to a standard curve to calculate the
numbers of live cells within each well. The viability of cells within the gel was assessed
with Live/Dead cell assay kit (Invitrogen) according to the Manufacturer’s instruction.
Scanning Electron Microscopy (SEM)
Fibrin matrices were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer
(PH 7.0) at room temperature for 1 hour. Samples were rinsed with phosphate buffer twice
with 10 minutes each. Matrices were sequentially dehydrated using 30%, 50%, 70%, 95%
(twice), 100% (twice) ethanol with 5 minutes for each treatment. Samples were then
sequentially treated using 33%, 66%, 100% (twice) hexamethyldisilane with 2 minutes for
each treatment. Samples were air-dried overnight before sputter-coated with goldpalladium and imaged with a scanning electron microscope (Hitachi S4700 Field-Emission
SEM, Hitachi, Tokyo, Japan).
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Animal experiment
The animal protocol was approved by the Institutional Animal Care and Use
Committee of the University of Nebraska-Lincoln. The experimental procedure was
performed in accordance with the guidelines of the Institutional Animal Care and Use
Committee of the University of Nebraska-Lincoln. Human MSCs were stained with
Vybrant DiI dye (V-22885, Molecular probe), and injected subcutaneously to the back of
the neck of NOD-SCID mice (Charles River Laboratory). 6 mice were used for the study.
For each mouse, 8 x 105 cells in 200 μl Ringer’s solution were injected to the left side of
the neck, and 8 x 105 cells with a fibrin matrix were injected to the right side of the neck
using a Tisseel-Duploject dual-syringe. Within the Tisseel-Duploject dual-syringe, one
syringe had 100 μl Ringer’s solution contained 10 mg/ml rFI and 4 x 105 MSCs, the other
syringe had 100 μl Ringer’s solution contained 0.16 mg/ml rFXIIIa, 20 U/ml rFIIa, and 10
mM CaCl2. The injected site was marked. After 24 hours, mice were euthanized. The skin
and connective tissue at and surrounding the injected site were harvested for analysis. The
harvested tissues were fixed with 4% PFA followed by soaking in 30% sucrose for 4 days.
Tissues were embedded in OCT and cryosectioned (vertical to the skin surface) with 40
μm thickness for each section. Tissue sections were imaged with a Zeiss Axio Observer
fluorescent microscopy. The total fluorescence intensity in the section that crosses the
needle track was quantified with Image J. software and used to evaluate the retention of
the injected MSCs at the injection site in each mouse.
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Statistical analyses
The data are presented as the mean ± S.D.. We used an unpaired t-test to compare
two groups and one-way ANOVA to compare more than two groups (GraphPad Software,
La Jolla, CA). P < 0.05 was considered statistically significant.
Results
Using mouse mesenchymal stem cells (D1 cells) to study the matrix compositionmatrix structure-cell behavior relationship
Effect of recombinant the thrombin (rFIIa) concentration
To study the effect of rFIIa concentration, the recombinant fibrinogen (rFI) and
activated recombinant factor thirteen (rFXIIIa) was fixed at 5 mg/ml and 0.04 mg/ml
respectively. The rFIIa concentration was varied from 1 U/ml to 15 U/ml (Figure 2.1).
Scanning electron microscope (SEM) images showed the fibrin fiber diameter, fiber
branching, fiber density and matrix pore size were similar between matrices made with
different rFIIa concentrations (Figure 2.1A). Cells exhibited a characteristic, spindle-like
morphology in all matrices after 2 days (Figure 2.1B). Live and dead staining on day 1
showed no obvious cell death in all matrices (Figure 2.1C). The total numbers of live cells
in the four matrices were similar on day 2 and day 4 (Figure 2.1D). These results showed
that the rFIIa concentration at the tested range had no significant influence on the matrix
structure and cell behaviors including cell morphology, viability, and the final live cell
numbers.
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Figure 2.1. Culturing D1 cells in 3D recombinant fibrin matrices made with different recothrombin (rFІІa)
concentrations (1 U/ml, 5 U/ml, 10 U/ml, 15 U/ml). Recombinant fibrinogen (rFІ) = 5 mg/ml; recombinant
factor thirteen (rFXIIIa) = 0.04 mg/ml; (A) Scanning electron microscope (SEM) images; (B) Phase images
at 4 h, day 2 and day 4; (C) Live dead cell staining of day 1 cells; (D) Cells in 100 μl fibrin matrix on day 2
and day 4 were quantified by alamar blue assay. Cell numbers were related to initial seeded cells.
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Effect of the rFXIIIa concentration
FXIIIa covalently crosslinks the fibrin matrix and enhances the stability of the
matrix. The yeast-produced activated recombinant FXIIIa has dimeric catalytic subunits
and has been under clinical studies45. To assess the effect of the rFXIIIa concentration, the
rFI and rFIIa was fixed at 5 mg/ml and 10 U/ml respectively. The rFXIIIa concentration
was varied from 0 mg/ml to 0.15 mg/ml (Figure 2.2). SEM images showed the fibrin fiber
diameter, fiber branching, fiber density and matrix pore size were very similar between
matrices made with different rFXIIIa concentrations (Figure 2.2A). Cells showed spindlelike morphology in all samples on day 2. However, the fibrin matrix without rFXIIIa had
significant degradation and shrank on day 4 (Figure 2.2B). Live and dead staining on day
1 did not detect evident cell death in all samples (Figure 2.2C). The alamar blue assay
showed a significantly higher cell number in the matrix without rFXIIIa on day 4, but there
was no significant difference between the other 3 matrices (Figure 2.2D). In summary,
rFXIIIa was required to form a fibrin matrix that could last 4 days in the presence of MSCs.
However, its concentration at the range from 0.04 mg/ml to 0.15 mg/ml had no significant
influence on the matrix structure and cell behaviors.
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Figure 2.2. Culturing D1 cells in fibrin matrices made with different recombinant factor thirteen (rFXIIIa)
concentrations (0 mg/ml, 0.04 mg/ml, 0.08 mg/ml, 0.15 mg/ml). rFІ = 5 mg/ml, rFІІa = 10 U/ml. (A) SEM
images; (B) Phase images at 4 h, day 2 and day 4; (C) Live/dead cell staining of day 1 cells; (D) Cells in 100
μl fibrin matrix on day 2 and day 4 were quantified by alamar blue assay. Cell numbers were related to initial
seeded cells. ****: p<0.0001.
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Effect of the rFI concentration
To study the effect of the rFI concentration, the rFIIa and rFXIIIa was fixed at 10
U/ml and 0.08 mg/ml respectively. The rFI concentration was varied from 5 mg/ml to 20
mg/ml (Figure 2.3). The SEM revealed that the fibrin matrix with higher rFI concentration
had more condensed and larger (in diameter) fibers (Figure 2.3A). Cells had spindle-like
morphology only in the fibrin matrix with 5 mg/ml rFI. Cells had round morphology in
fibrin matrices with 10, 15 and 20 mg/ml rFI (Figure 2.3B). Significant cell deaths were
observed in matrices with 10, 15 and 20 mg/ml rFI using live and dead staining on day 1
(Figure 2.3C). During the 4 day culture, the cell number increased in the matrix made with
5 mg/ml rFI, while they decreased in other groups, especially in matrices with 15 and 20
mg/ml rFI (Figure 2.3D). These results showed that, unlike rFIIa and rFXIIIa, the
concentration of rFI had a significant effect on the matrix structure, cell morphology,
survival and/or growth.

20

Figure 2.3. Culturing D1 cells in fibrin matrices made with different recombinant fibrinogen (rFІ)
concentrations (5 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml). rFІІa = 10 U/ml, rFXIIIa = 0.08 mg/ml. (A) SEM
images; (B) Phase images at 4 h, day 2 and day 4; (C) Live dead cell staining of day 1 cells; (D) Cells in 100
μl fibrin matrix on day 2 and day 4 were quantified by alamar blue assay. Cell numbers were related to initial
seeded cells. ****: p<0.0001.
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Validate the findings with human MSCs (hMSCs)
To study if the above findings with mouse MSCs can be translated to hMSCs, we
selected 5 representative formulations for culturing human bone marrow MSCs (Figure 4).
In the matrix made with 5 mg/ml rFI, 0.08 mg/ml rFXIIIa and 10 U/ml rFIIa, (labeled as
(5, 0.08, 10) or the control group), hMSCs had spindle-like morphology after 2 days and
no significant cell death was observed by live and dead staining (Figure 2.4A and 2.4B).
When the rFI concentration was increased to 10 mg/ml (labeled as (10, 0.08, 10)), cells
showed no spreading even after 4 days. The Live and dead staining detected significant
dead cells (Figure 2.4A and 2.4B). There was significantly less cells in this matrix on both
day 2 and 4 (Figure 2.4C). When the rFIIa concentration was decreased to 5 U/ml (5, 0.08,
5), the cell morphology, viability and numbers were very similar to these of the control
group. There was much more cells in the matrix without rFXIIIa (5, 0, 10) than other groups.
We observed significant matrix degradation for this condition on day 1 (Figure 2.4D).
hMSCs in the matrix made with 0.15 mg/ml rFXIIIa (5, 0.15, 10) were very similar to cells
in the control matrix. In short, the recombinant fibrin matrix compositions had similar
effects on mouse and human mesenchymal stem cells. Fibrin matrices made with rFI higher
than 5 mg/ml were inappropriate for hMSC culture.
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Figure 2.4. Culturing human MSC cells in fibrin matrices made with different rFІ, rFXIIIa, and rFІІa
concentrations. Group 1: rFІ = 5 mg/ml, rFXIIIa = 0.08 mg/ml, rFІІa = 10 U/ml; Group 2: rFІ = 10 mg/ml,
rFXIIIa = 0.08 mg/ml, rFІІa = 10 U/ml; Group 3: rFI = 5 mg/ml, rFXIIIa = 0.08 mg/ml, rFІІa = 5 U/ml;
Group 4: rFІ = 5 mg/ml, rFXIIIa = 0 mg/ml, rFІІa = 10 U/ml; Group 5: rFI = 5 mg/ml, rFXIIIa = 0.15 mg/ml,
rFІІa = 10 U/ml. (A) Phase images at 4 h, day 2 and day 4; (B) Live/ dead cell staining of day 1 cells; (C)
Cells in 100 μl fibrin matrix on day 2 and day 4 were quantified by alamar blue assay. Cell numbers were
related to initial seeded cells; (D) The fibrin matrix without rFХIII had significant degradation on day 1. The
white cycles indicate areas with significant degradation. ****: p<0.0001, ***: p<0.001, *: p<0.05.

Deliver hMSCs with fibrin matrix
Lastly, we studied if the recombinant matrix could be used to deliver hMSCs and
enhanced their retention at the injection site. The fibrin matrix with 5 mg/ml rFI, 0.08
mg/ml rFXIIIa and 10 U/ml rFIIa was used because the in vitro cell culture experiment
found it was stable for at least 4 days, supported high cell viability and reasonable cell
growth (Figure 2.4C). hMSCs were labeled with fluorescent Dil dyes and injected
subcutaneously to NOD-SCID mice. Using the fibrin matrix, significantly higher numbers
(two-fold) of cells were retained at the injection site (Figure 2.5).

Figure 2.5. Deliver hMSCs with recombinant fibrin matrices. hMSCs were labeled with Dil dyes and injected
subcutaneously into NOD-SCID mice without (A) and with the fibrin matrix (B) (rFI = 5 mg/ml, rFXIIIa =
0.08 mg/ml, rFІІa = 10 U/ml). Representative fluorescent images of the labeled MSCs at the injection sites
from three mice were shown. (C) The relative fluorescent intensities at the injection sites of the two
transplantation groups. 6 mice were used for the analysis. ***: p<0.001.
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Conclusion
Recombinant fibrin matrices, which have lower cost and risk of the human
pathogen transmission, are very attractive for MSCs culture and delivery42,43. For the first
time, our studies found fibrin matrices made with entirely recombinant proteins were
suitable for culturing and delivering MSCs. We found the protein formulation affected both
the matrix structure and the cell behaviors. Increasing the rFI concentration led to larger
fiber diameter and denser matrix, and in turn, significantly reduced the cell viability,
inhibited cell spreading and growth. Our studies showed fibrin matrices with rFI
concentration above 5 mg/ml could not support efficient cell survival (Fig. 3 and 4). Both
rFIIa and rFXIIIa were required to form stable fibrin matrices. However, their
concentrations at the tested range had a minor influence on the matrix structure and cell
behaviors (Fig. 1, 2 and 4). The totally recombinant fibrin matrix could be used to deliver
MSCs and enhanced their retention at the injection site. Future research should investigate
the long-term effect of the fibrin matrix on cell survival, integration, and function. It will
also be valuable to use clinic-relevant disease models such as myocardial infarction and
stroke to test the capability of the matrix to retain the cells at the injection sites.
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CHAPTER 3.

THE SYNTHESIS OF A RECOMBINANT FACTOR XIII

CROSS-LINKED γγ’-FIBRIN MATRIX HAVING PERIODIC
FIBRONECTIN NANOBANDS THAT ACCELERATE WOUND CLOSURE
Introduction
Plasma fibrinogen (F1) consists of two bio-monomer sub-populations when
integrated with plasma fibronectin (pFN) form fibrin polymer that is both a hemostatic
barrier1–5 and a provisional matrix needed to initiate wound healing6–10. Purified fibrinogen
formulations used to form fibrin for culturing cells associated with healing have long been
reconstituted to the same mass ratio of 1 fibrinogen to 10 pFN as found in plasma to help
optimize colonization of human fibrin in vitro11. F1 is linear fibrin precursor that is a
hexameric, 340 kDa glycoprotein that includes 2 gamma chains1,2,12,13 while is pFN is a 2chain globular, 440 kDa protein. Importantly, about 90% of F1 occurs in circulation as a
homodimeric pairing of γ-chains (γγF1)14 with the remaining occurring as a heterodimeric
pairing of γ with a slightly larger, more acidic γ’-chain (γγ’F1) that is associated with a
pleotropic biology of vascular health15,16. Furthermore, pFN and γγ’F1 coincidentally both
occur at about the same concentration in plasma of about 300 µg/ml16–19.
The formation of the fibrin:pFN polymer begins with thrombin mediated activation
of γγF1,γγ'F1 and Factor XIII (pFXIII). The activated fibrinogens produce a semi-soluble,
viscoelastic fibrin aggregate1–3 containing pFN entrained from plasma. The pFXIII is
inherently present within the polymerizing fibrin aggregate as a complex with 1 out of
every 100 γγ'F1 molecules15 which disassociates upon formation of activated pFXIII
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(pFXIIIa) so as enable efficient intra-fibrin cross-linking activity. This results both in the
insoluble pFN:fibrin matrix4,11,20–22 and its simultaneously cross-linked to the wound
surface over the course of about 3 minutes15,23.
The wound anchored pFN:fibrin also catalyzes healing by the dual colonization of
fibroblasts and endothelial cells (ECs) which forms a provisional vascularized tissue called
‘granulation tissue24,25. It does this through different mechanisms for fibroblasts than for
endothelial cells where the colonization by ECs is more tenuously dependent on pFN4,11,26.
For example, fibroblasts have cellular receptors that recognize R-G-D residues that are
presented by pFN after conformational changes induced by FXIII-crosslinking11,27–30. In
contrast, the predominant interaction of endothelial cells (EC)31,32 with fibrin is by VECadherin cellular receptors which bind to the β-chain of cross-linked fibrin. Furthermore,
the presence of vascular endothelial growth factor (VGEF) and fibroblast growth factor 2
(FGF-2) in cell culture media has been shown to be necessary for catalyzing the EC
colonization of fibrin in vitro31–33. Thus, far the influence on EC colonization at the length
scale of the 3-D fiber presented by the pFN:fibrin matrix has not been well detailed.
The general fiber structure and biological activity of fibrin made from purified
γγ’F1 or γγF1 but without discernable levels of pFN has been recently studied7,15,23. While
there were subtle differences in fiber structure, fibrins made from either γγ’F1 or γγF1
induced similar levels of angiogenesis by ECs in wound healing studied in a normal mouse
model7. We here describe the synthesis of a viscoelastically strong, 1:1 γγ’F1:pFN fibrin
having fibers periodically wrapped with a pFN nanostructure. We report on the ability of

34

this matrix to enhance EC colonization in vitro and wound closure in a normal mouse
model.
Materials and Methods
Materials
All reagents were obtained from Sigma Chemical Company (St. Louis MO) unless
otherwise noted. Human source plasma was provided by the U.S. Army Materials
Command (Fort Detrick, MD.). Recombinant human thrombin was purchased from
ZymoGenetics (Seattle, WA). DEAE Sepharose fast flow, Superose 6 and Gelatin
Sepharose were purchased from GE Healthcare (Uppsala, Sweden). 4-12% NuPage BisTris SDS polyacrylamide gels, Colloidal Blue stain and See Blue molecular weight markers
were from Invitrogen (Carlsbad, CA). Polyclonal antibody (GMA-034) for human
fibrinogen (1:100) was purchased from Green Mountain Antibodies (Burlington, VT).
Antibody (ab2413) for human fibronectin (1:200) was from Santa Cruz Biotechnology.
Antibodies were reconstituted according to manufacturer’s instruction.
Recombinant Factor XIII
Recombinant Factor XIII (rFXIII) was made in Pichia pastoris according the
methods of Park34,35. Briefly, the rFXIII was purified from cell lysates using Ni-IMAC
from GE Healthcare. The activity was determined using Pefakit (Pentapharm, Norwalk,
CT). The final specific activity of the >95% purity preparations was typically 154 ± 19
Plasma FXIII Equivalent Units/mg (PEU/mg) where the specific activity of pFXIII was 25
u/mg using a peptide incorporation cross-linking assay.
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Preparation of fibrinogen and fibronectin from human plasma
Three units of human plasma that had been stored at -80 ºC were thawed at 4 ºC.
The plasma was centrifuged at 4000 rpm for 20 min. The supernatant was re-frozen and
stored for subsequent purification of fibronectin and other plasma-derived proteins. The
cryoprecipitate was re-suspended in 45 mM sodium citrate, 100 mM 6-aminocaproic acid,
pH 7.0 at 37 ºC. The solution was then centrifuged for 25 min at 4000 rpm. The pellet was
discarded, and the supernatant was treated with a solvent detergent viral inactivation step
by addition of 0.15% TnBP, 0.5% Triton X-100 and stirred at room temperature for 60 min.
The solvent-detergent treated supernatant was adjusted to 1 M ammonium sulfate by
addition of a 4 M stock. The sample was stirred at room temperature for 30 min, and then
centrifuged at 2000 rpm for 15 min at room temperature. The pellet was re-suspended in
20 mM sodium citrate, 100 mM NaCl. The sample was dialyzed overnight at room
temperature against the same buffer. The dialyzed sample was centrifuged at 2000 rpm for
15 min at room temperature. Any resulting pellet was discarded.
The supernatant was fractionated further to isolate γγF1, γγ’F1 and pFN as
described by Siebenlist et al36 using DEAE Sepharose Fast Flow chromatography at room
temperature. The sample was applied to a DEAE column then washed with 10 column
volumes of 20 mM sodium citrate, 100 mM NaCl, pH 7.4. The unabsorbed fraction was
γγF1. Bound protein was eluted with a linear gradient of 0.1 M to 1.0 M NaCl. The pooled
eluate from the DEAE resin produced an approximately equimolar mixture of γγ’F1 and
pFN that was dialyzed against 20 mM citrate buffer, 20 mM NaCl at pH 6.8. The dialyzed
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mixture was concentrated using a 10 kDa centrifugal ultrafiltration device at 4000 g for 30
min.
Pure pFN and γγ’F1 were produced by application of the DEAE eluate pool to
gelatin-Sepharose. Briefly, a 10 ml γγ’F1:pFN mixture was applied to a 3 ml analytical
gelatin-Sepharose column. The column was washed with 10 volumes of the dialysis buffer
then eluted with the same buffer containing 6 M urea. Samples were analyzed by SDSPAGE. pFN was eluted by urea while the γγ’F1 fell through the column.
2D adhesion assay
Human foreskin fibroblasts were isolated and cultured in DMEM with 10%
FBS10,37. The use of primary human fibroblasts from anonymous donors (no subject
identifiers and no informed consent) without the use of informed consent was approved by
the Institutional Review Board at the University of Nebraska Medical Center and by the
Research and Development Committee at the Omaha VA Medical Center. Passage 4 to 6
cells were used. HUEVCs were purchased from Lonza and cultured in EGM2 medium.
Passage 3 and 4 cells were used for the experiments. 100 µl fibrin matrix was made in one
well of the 96-well plate. 1x104 cells were placed in each well with 200 µl medium. 3 hours
after plating, medium and unattached cells were removed. Cells were washed with 200 µl
PBS once. Attached cells were recorded with phase-contrast microscope. Alternatively, the
cells were fixed with 4% PFA and stained with DAPI. The nuclei were recorded with
fluorescence microscope. 100 µl fresh medium with 10 µl alamar blue reagent were added
and incubated for 3 hour. 100 µl medium was collected for measuring the fluorescence that
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was calibrated to a standard curve to calculate the numbers of attached cells within each
well.
3D cell culture within fibrin matrix
100 µl fibrin matrix with 2x104 cells were made in individual wells of a 96-well
format plate. 200 µl medium was added to each well. At varied time points after plating,
cell morphologies were recorded by phase-contrast microscopy. The medium was removed
and 100 µl fresh medium with 10 µl alamar blue reagent were added and incubated for 3
hour. 100 µl medium was collected for measuring the fluorescence that was calibrated to a
standard curve to calculate the numbers of cells in each matrix. The viability of cells within
the gel was accessed with Live/Dead cell assay kit (Invitrogen) according to the
Manufacturer’s instruction.
Fibrin formulation
To make the fibrin matrix for the above cell culture experiment, the following fibrin
formation components were mixed to the final concentration of the respective fibrinogen
(γγF1, γγ’F1) of 2.5 mg/ml total protein; thrombin at 1 U/ml; factor XIIIa at 15.4 U/ml;
and 3.3 mg/ml pFN. The mixtures were incubated at 37 ºC for 15 min to form the fibrin
matrix.
SEM and confocal microscopy
Fibrin matrices were made according to the formulation above. For SEM, samples
were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer (PH 7.0) at room
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temperature for 1 hour, then at 4 ºC overnight. Samples were rinsed with phosphate buffer
twice, 10 minutes each. Ethanol dehydration series were performed: 30%, 50%, 70%, 2 x
95%, 2 x 100%, 5 minutes for each procedure. Then samples were treated with
hexamethyldisilazane (HMDS) as following: 33% HMDS, 66% HMDS, 2 x 100% HMDS,
2 minutes for each procedure. Samples were left in 100% HMDS to air-dry at least
overnight. before sputter-coated with gold-palladium and imaged with the scanning
electron microscope (Hitachi S4700 Field-Emission SEM, Hitachi, Tokyo, Japan) at 10 kV
and a magnification of 30000. For confocal microscopy, samples were fixed with 4%
paraformaldehyde (PFA) at 4 ºC overnight, washed with PBS for 3 times, permeabilized
with 0.25% Triton X-100 for 15 minutes, and blocked with 5% goat serum for 1 hour before
incubating with primary antibodies at 4 ºC overnight. After extensive washing, secondary
antibodies were added and incubated for 2 hours at room temperature and. Samples were
then washed with PBS before imaged with confocal microscope (Nikon A1-R confocal
system on a Nikon Eclipse 90i upright fluorescence microscope).
Animal research
All animal protocols were approved by the Institutional Animal Care and Use
Committee of the University of Nebraska-Lincoln. All experimental procedures involving
animals were performed in accordance with the guidelines of the Institutional Animal Care
and Use Committee of the University of Nebraska-Lincoln. The mouse excisional wound
splinting model was descripted previously38. Briefly, donut-like splints with 5-mm
diameter of the center hole and 15-mm diameter of the disc were created. The splints were
sterilized in 70% ethanol before experiment. Mice were anesthetized. Two symmetrical 5-
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mm full-thickness excisional wounds were created on the back of each mouse. The splint
was carefully placed around the wound and secured to the skin with eight interrupted
sutures. The left wound was sealed with 50 μl γγ'F1:pFN fibrin matrix, while the right
wound was added with 50 μl γγF1:pFN fibrin matrix. The total protein concentration are
2.5 mg/ml fibrinogen and 3.3 mg/ml fibronectin; 15.4U/ml rFXIII, 0.2 μg/ml VEGF, and
1 U/ml recombinant thrombin were used to form the fibrin matrix. The wounds were
covered with sterile transparent dressing. On days 2, 4, 6, and 9, additional 20 μl of the
fibrin matrix were added to the wounds.
Frozen section and Hematoxylin and Eosin (H&E) staining
Mice were sacrificed on day 15. The wound tissues were carefully harvest. The
wound area was calculated before dissecting each wound across the center into two equal
pieces. The wound tissues were fixed in cold 4% (wt/vol) paraformaldehyde in PBS at 4 °C
overnight and submerge into 30% sucrose in PBS at 4 °C until the sinks. Tissues were
embedded in OCT compound and freeze in - 70 °C. 40-µm thick cryostat sections were cut.
The sections were wash with PBS subsequently stained with hematoxylin (RICCA,
Arlington, TX) and eosin. Images were taken by EVOS® FL Auto Cell Imaging System.
Statistical analyses
The data are presented as the mean ± S.D.. We used an unpaired t-test to compare
two groups and one-way ANOVA to compare more than two groups. P < 0.05 was
considered statistically significant.
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Results
The naturally occurring mass ratio of pFN within the total F1 population in human
plasma is about 1:10 and which naturally coincides with about a 1:1 molar ratio of pFN
with the γγ’F1 subpopulation. Our experimental focus reported here is the study in vitro
and in vivo of novel cross-linked fibrin matrices using recombinant Factor XIII (rFXIII)
made from each of the fibrinogen sub-populations and with or without pFN.
Fibrin formulation and material characteristics
The biological function related to the naturally occurring plasma ratios of pFXIII,
pFN, and F1 have been established in the context of normal hemostasis and wound healing
in vivo. Here we have focused on enhancing this function by making a unique cross-linking
of pFN into fibrin made either from γγF1 or from γγ’F1. We do this in the context of the
natural 1:1 ratio that γγ’F1 occurs with pFN while using much higher levels of crosslinking activity supplied by rFXIII. We made high purity γγF1, γγ’F1 and pFN from human
plasma as shown by Coomassie blue stained SDS-PAGE under reducing conditions
(Figure 3.1A). As part of that processing and due to their similar degrees of acidity, we
were able to purify a fraction which contained an approximately 1:1 γγ’F1 and pFN (here
designated γγ’F1:pFN). The rFXIIIa used here had a novel specific cross-linking activity
was 154 U/mg which was about 6-fold higher than plasma-derived FXIII (Figure 3.1B).
We used a commercially available, biotherapeutic grade recombinant thrombin and our
rFXIIIa to make fibrin matrices from based upon the naturally occurring stoichiometric
plasma molarity of γγ’F1 and pFN (Figure 3.1C-F). Fibrins made at the same fibrinogen
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concentrations were evaluated when made from γγF1 alone, γγ’F1 alone, and the 1:1
γγ’F1:pFN obtained from the DEAE eluate fraction and a 1:1 mixture of γγF1 and pFN
(designated here as γγF1:pFN).
We characterized both the kinetics of the formation of the fibrins and the resulting
viscoelastic strengths of the fibrins made at different levels of rFXIII using TEG (Figure
3.1C-F) where the data range bars are small or almost imperceptible. The highest strength
obtained at the lowest F1 concentration which the TEG could reliably measure occurred at
about a 5:1 molar ratio of F1 to rFXIII (Figure 3.1C-F). This rFXIIIa activity level was
estimated to be about 20-fold or higher (2 units/nmol F1) than the trace amounts of FXIII
activity that typically associates with the γ’ chain of γγ’F1 (estimated to be 0.08 units/nmol
F1) and which typically co-purifies with biotherapeutic grade plasma F1 products. All
treatment groups of different rFXIII levels respectively possessed a similar time course
polymerization pattern and an equivalent viscoelastic strength. Interestingly, the presence
of a 1:1 total F1 to pFN molar ratio (Figure 3.1D, 3.1F) further lowered the viscoelastic
strength of both fibrins made from γγF1 or γγ’F1 showing the impact of pFN in the
fibrin:pFN polymerization process.
Our studies chose the fibrin formulation with the lowest level of 2.5 mg/ml F1 while
at a level of rFXIII activity as to produce a fibrin facile for wound application in the studies
presented below. All of these fibrins made with or without pFN yielded a sufficiently stable
tissue sealant with rapid wound adhesion as applied in our mouse model studies. In
summary, for in vitro cell culture analysis and in vivo wound applications, we chose a level
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of 15.5 U/ml rFXIIIa to sufficiently stabilize the fibrin by cross-linking the fibrins at the
low level of 2.5 mg/ml of γγ’F1 or γγF1.
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Figure 3.1. Material characteristics. (A) Reducing SDS-PAGE gel. (B) rFXIIIA1 activity (153.5 ± 19 U/mg)
was estimated by the 5-(biotinamido) pentylamine incorporation assay. The effect of rFXIIIa on the
viscoelastic and clotting kinetics of γγF1 (C), γγF1 and pFN (D), γγ’F1 (E), and γγ’F1 and pFN (F) were
evaluated by TEG assay.
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Our in vitro studies of the fibrins focused primarily on culture behavior most
relevant to the wound healing phenomena associated with fibroblasts and ECs8,27. Figure
3.2A shows the fiber networks we observed by SEM for the four fibrin formulations. All
matrices showed a similar frequency of branch points and the similar range of fiber
diameters ranging primarily from about 250 to 350 nm. Generally, F1 reactive
immunostaining to either γγF1 or γγ’F1 and confocal microscopy was used to study the
distribution of pFN within the fibrin matrices (Figure 3.2B, 3.2C). A sporadic appearance
of irregularly sized pFN aggregates was observable within the fibrin matrix made from
γγF1:pFN. In contrast, the fibrin made from the γγ’F1:pFN mixture presented pFN
aggregates as a regularly occurring banded structure that was wrapped around the fibers
with an axial dimension of about 300-400 nm that was displayed throughout the matrix
(Figure 3.2B, 3.2C).
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Figure 3.2. Scanning electron microscopy (A) and confocal microscopy (B) images of fibrin matrices
made from γγF1, γγ’F1, a 1:1 mixture of γγF1 and pFN, or a 1:1 mixture of γγ’F1 and pFN. (C) Zoomin images of squared areas in (B).
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In vitro evaluation of fibrin biological activity for fibroblasts
Fibroblasts have been previously shown to grow robustly on fibrin in the presence
of pFN made from a ratio of 10 F1 to 1 pFN7,27–30. The adhesion of fibroblasts to the surface
of our fibrin matrices was measured on 2-D format for 3 hours which is a time established
to be sufficient for cellular adhesion (Figure 3.3A). The nuclei of attached fibroblasts were
stained by DAPI. Adhered cells were also quantified with alarmar blue assay (Figure
3.3D). These 2-D culture results showed nearly 100% of the plated fibroblasts adhered to
all four of these matrices. We observed fibroblasts after embedding within each of the 4
fibrin matrices (Figure 3.3B, 3.3C). After 48 hours of this 3-D culturing a normal and
healthy progression to an extended morphology occurred within all matrice types. Good
viability was also indicated by live/dead cell staining. In particular, the fibroblasts had
expanded about 6-fold within γγ’F1:pFN matrix and about 4-fold in each of the other three
fibrin formulations. Thus, all of the fibrin materials induced fibroblast viability which was
similar to that reported in the literature for fibrin with or without pFN7,27–30.
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Figure 3.3. Culturing primary human fibroblasts on top of (A,D) and within 3D fibrin matrices (B,C,E). (A)
The nuclei of cells attached to fibrin matrices at 3 hr. (B) Fibroblasts in 3D fibrin matrices at 2 h and 48 h.
(C) Live and dead cells at 48 h. (D) Cells attached to the fibrin matrices were quantified with alamar blue
assay. (E) Cells in 100 μl fibrin matrices at 48 h were quantified with alamar blue assay. Cell numbers are
related to the initial seeded cells. **: p<0.01.

48

In vitro evaluation of fibrin biological activity for ECS
Recent studies have shown that culture of ECs on γγF1 or γγ’F1 fibrin is greatly
more tenuous than the culture of fibroblasts using preparations which showed no visible
pFN content by SDS-PAGE. Our studies showed that HUVECs cultured in 2-D exhibited
some degree of adherence after 3 hours to all fibrin matrices studied here (Figure 3.4A).
However, quantification showed that nearly 100% of HUVECs attached to the 2-D
γγ’F1:pFN matrix, while only about 50% of HUVECs attached to the other three fibrin
matrices (Figure 3.4D). We then used 3-D culture of HUVECs within the fibrin matrices:
after 48 hours on γγF1, γγ’F1, and 1:1 γγF1:pFN fibrin matrices showed spherical
morphology, indicating a poor adhesion that is characteristic of apoptosis (Figure 3.4B,
3.4C). This apoptotic profile was confirmed by live/dead cell staining (Figure 3.4C). In
contrast, HUVECs cultured within γγ’F1:pFN showed no evidence of apoptosis while
having a high level of morphologically healthy sprouting. Quantification clearly showed a
3-fold expansion of these ECs within the γγ’F1:pFN matrix relative to the low level of
expansion observed for the other fibrins (Figure 3.4E).
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Figure 3.4. Culturing primary human umbilical vein endothelial cells (HUVECs) on top of (A,D) and within
3D fibrin matrices (B,C,E). (A) HUVECs attached to fibrin matrices at 3 h. (B) HUVECs in 3D fibrin matrices
at 30 min and 48 h. Red and black arrows point to apoptotic and live cells, respectively. (C) Live and dead
cells at 48 h. (D) Cells attached to the fibrin matrices were quantified with alamar blue assay. (E) Cells in 100
μl fibrin matrices at 48 h were quantified with alamar blue assay. Cell numbers are related to the initial seeded
cells. ***: p<0.001 and ****: p<0.0001.
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In vivo wound mouse dermal wound closure model
We studied healing in wounds sealed by γγ’F1:pFN fibrin using paired, dermal
wound model in normal mice. We paired the 1:1 γγF1:pFN mixture as the wound control
treatment group because it did not form a banded pFN fibrin nanostructure. Successive
wound sealing applications were done on day 0, 2, 4, 6 and 9 for each of the two treatments
that were juxta-positioned within each given mouse. After 15 days, we observed that the
open area of the wounds sealed with fibrin made from γγ’F1:pFN were smaller relative to
that treated with fibrin made from γγF1:pFN (Figure 3.5A, 3.5D ). Histology showed a
native granulation tissue profile across the remaining, not fully closed wound surface
(typical histological cross-section shown in Figure 3.5B), where open wounds treated with
fibrin made from γγF1:pFN were markedly less advanced towards closure (zoomed in view
Figure 3.5C).
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Figure 3.5. Mouse skin wounds treated with fibrin matrices. (A) Wounds treated with γγF1:pFN or
γγ’F1:pFN matrix on day 15. (B) H&E staining.( C) Zoom-in images of squared areas in (B). (D) Wound
areas on day 15. *: p<0.05.
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Discussion and conclusion
Our fibrin engineering is based upon the pleotropic biological activities of γγ’F1
with respect to vascular physiology15 and the known catalytic properties of pFN for wound
healing. Fibronectin also plays a mechanical role in augmenting fibrin strength.
Furthermore, both γγ’F1 and pFN occur at nearly a 1:1 molar ratio in normal human
plasma16,18,19,29. This is consistent with the 1:10 ratio of pFN to F1 typically present in
fibrinogen preparations that is considered an optimal composition for fibrin based cell
culture of fibroblasts11. Fibronectin also plays a mechanical role in augmenting fibrin
strength5,25. We were able to produce a mixture containing a 1:1 ratio of pFN and γγ’F1
using anion exchange chromatography of fibrinogen-pFN concentrates obtained by
classical precipitation. This procedure exploited the similar acidity of pFN and γγ’F1 and
also enabled isolation of γγF1. We further isolated pFN from the γγ’F1 DEAE eluate
mixture using collagen affinity chromatography. The fibrins respectively made here from
the core γγ’F1 and γγF1 and were similar in formation kinetics as measured by TEG, range
of fibrin diameters and branch points. The γγ’F1:pFN and γγF1:pFN fibrins were stronger
than respective γγ’F1 and γγF1 formulations confirming that the presence of pFN
strengthens fibrin.
The cross-linking activity needed for the formation of an effective hemostatic fibrin
barrier and integration of pFN is normally supplied by a complex of pFXIII with γγ’F117,23.
Here we augmented this activity by >20-fold using rFXIII to produce a strong fibrin matrix
when formed over a range of 2.5-4.5 mg/ml F1. In general, we observed that decreasing
the F1 levels resulted in fibrin mechanical properties that provided more dexterous mouse
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wound application were effectively made at the F1 levels which normally occur in human
plasma. However, a facile kinetic balance between rapid polymerization and wound
adhesion of the fibrin during wound surface application was possible due to the high levels
of rFXIII activity.
Importantly, the elevated cross-linking activity here also induced the formation of
pFN aggregates. Relative to the other fibrins studied, the γγ’F1:pFN fibrin was unique in
its high efficiency for both fibroblast and EC colonization in vitro as well as normal wound
closure and healing. Because of the similarities in core fiber matrix structure among all
fibrins studied here, the enhanced interaction of ECs with γγ’F1:pFN fibrin was likely due
to its unique presence of the pFN aggregate fiber wrappings. An enhanced ability of ECs
to engage with the γγ’F1:pFN fibrin was observed with both 2-D and 3-D culture
experiments: the 2-D culturing of ECs showed a rapid establishment of cell adhesion points
which initiated cell elongation while the 3-D culture showed robust survival, proliferation
and vascular morphogenesis. In contrast, the other fibrins were associated with a greater
extent of apoptosis in 3-D culture. To our knowledge, this is the first report of enhanced
EC colonization and healing using a γγ’F1:pFN fibrin matrix.
The initiation of cellular engagement by fibroblasts with fibrin containing pFN is
well known to be provided by FXIII cross-linking that converts pFN to a conformationally
active form11. However, this activity has not been specifically associated with EC
recruitment by pFN so as to result vascularization of granulation tissue24,31. Our study
supports an rFXIII induced activation of pFN conformation within the aggregate wrappings
that are periodically presented throughout the γγ’F1:pFN fibrin matrix. In contrast, the
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sporadically occurring and irregular aggregates of pFN formed within the γγF1 fibrin did
not enhance EC colonization. It is noted that VEGF and FGF-2 are known to promote the
initial colonization of either γγ’F1 or γγF1 fibrin by EC32,33 but not the entire sequence
leading to vascular morphogenesis.
In summary, our wound healing results reinforce the enhanced colonization of both
EC and fibroblasts on γγ’F1:pFN fibrin that were observed in vitro. Fibroblasts cultured in
3-D have been shown to be stimulated on collagen that axially presented aggregates of
about 90 pFN molecules that were dispersed along the matrix fibers. 37,39 In the future, we
will continue our in vitro study of the EC colonization and potential integrin-pFN activity
with the pFN wrapped γγ’F1 fibers and its impact on the vascularization phenomena
associated with wound healing
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CHAPTER 4.

ENGINEERED HUMAN BROWN ADIPOCYTE

MICROTISSUES IMPROVED GLUCOSE AND INSULIN HOMEOSTASIS
IN HIGH FAT DIET-INDUCED OBESE AND DIABETIC MICE
Introduction
According to World Health Organization data, about 10% of adults have obesity
(OB), and the population with OB-associated T2DM will reach 300 million by 20251.
There are currently no safe and long-lasting approaches to prevent/treat OB and T2DM2.
Healthy humans have a substantial amount of BAT, a tissue that augments the whole-body
energy expenditure. Large clinical data shows BAT activity inversely correlates to body
mass index, plasma glucose, and triglycerides levels, and insulin resistance, and BAT
activity is a negative predictor of T2DM, dyslipidemia, coronary artery disease,
cerebrovascular disease, congestive heart failure, and hypertension3–5. Furthermore, the
beneficial effects of BAT are more pronounced in obese individuals, suggesting the
importance of this tissue for the obese population3–5.
Clinical studies have shown that augmenting BAT activities using pharmaceuticals
(e.g., mirabegron6, glucocorticoids7, BIBO33048), or cold stimulation9–12 enhances the
whole-body energy expenditure, glucose tolerance, and insulin sensitivity13–15. These
findings suggest that BAT is a promising therapeutic target. However, these BATactivating approaches require sustained treatments, have significant side effects16, and may
not work long-term. Additionally, they may work poorly on patients with a low abundance
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of BATs, such as obese and senior individuals (a population mostly affected by OB and its
associated diseases).
An alternative approach to overcome these problems is to augment BAT mass and
activity via tissue transplantation. Several groups transplanted BAT (0.1-0.2 g) from
healthy mouse donors to diet-induced or genetically obese mice17–20. The transplantation
significantly reduced plasma glucose, triglyceride, lipid levels, body weight gain, fat
composition, and hepatic steatosis19,20 while increasing the body energy expenditure,
oxygen consumption rate (OCR), glucose homeostasis, and insulin sensitivity21,22.
Transplanted BAT could directly burn fatty acids and glucose and dissipate the energy as
heat via non-shivering thermogenesis (e.g., act as an energy sink)15,16. They also secreted
soluble factors and exosomes that enhanced glucose uptake and energy expenditure in the
heart, muscle, and WAT (e.g., act as an endocrine organ)13,23–27. Although few studies have
used T2DM mice as recipients, research found that transplanting mouse BAT into
streptozotocin (STZ)-induced diabetic mice prevented and reversed type 1 diabetes
mellitus (T1DM)21,28.
To date, most transplantation studies used mouse BATs, and it is uncertain whether
these therapeutic effects, cellular and molecular mechanisms would be applied to human
BAT since human and mouse BATs have distinct differences29. However, human BAT is
located at deep organs, e.g., the supraclavicular, perirenal/adrenal, and paravertebral
regions, and isolating sufficient human BAT for transplantation and research is
challenging30. The Tseng group recently isolated and immortalized human brown
adipocyte progenitors (BAPs) and found that these BAPs, when transplanted with Matrigel,
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could prevent/reverse diet-induced OB and metabolic disorders31. Interestingly, they also
showed that human white preadipocytes activated to express endogenous UCP-1 had
similar effects, indicating the importance of UCP-1 protein32. The study transplanted a
large number (1.5-2x107 cells per animal) of proliferating BAPs, which have potential
tissue overgrowth risk. It also used Matrigel, an extracellular matrix (ECM) extracted from
mouse tumors that contain hundreds of undefined components. Matrigel is not compatible
with clinical applications.
To address these limitations, we explored if transplanting a low dose of mature BAs
(differentiated from the above BAPs) in the absence of Matrigel could alleviate HFDinduced OB, metabolic symptoms, and T2DM in mice. When harvesting the fully
differentiated BAs cultured in the conventional two-dimensional (2D) cell culture dishes,
the trypsin-based dissociation killed a large percentage of cells. Additionally, the remaining
BAs had a very low survival rate after transplantation. We thus proposed to prepare
injectable 3D BA microtissues to overcome these problems. Here, we report the BA
microtissue fabrication method, their survival, safety, and capability to improve glucose
and insulin homeostasis and manage body weight gain in HFD-induced OB and diabetic
mice.
Materials and Methods
2D cell culture and differentiation
Immortalized BAPs are gifts from Dr. Tseng at Harvard University(Xue et al>,
2015). We followed published methods to culture BAPs34,35. Briefly, BAPs were cultured
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in Dulbecco’s Modified Eagle Medium (DMEM, HyClone, #SH30003.03) supplemented
with 10% FBS (Atlanta biologicals, #S11150). When cells reached 80% confluence, they
were passaged (1:3) with 0.25% trypsin-EDTA (Giboco, #25200056). To induce
differentiation, BAPs were seeded at 0.5x104 cells/cm2 and maintained in the growth
medium to reach confluence. Then cells were cultured in differentiation medium I
consisting EBM-2 (Lonza, #CC-3156), 0.1% FBS, 5 μM SB431542 (Selleckchem,
#S1067), 25.5 μg/ml ascorbic acid (Sigma, #A89605G), 4 μg/ml hydrocortisone (Sigma,
#H0396), 10 ng/ml Epidermal Growth Factor (Peprotech, # 100-15), 0.2 nM 3,3′,5-TriiodoL-thyronine (T3, Sigma, #T2877), 170 nM insulin (Sigma, #I9287-5ML), 1 μM
rosiglitazone (Sigma, #R2408), 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX, Sigma,
#I5879) and 0.25 μM dexamethasone (Sigma, #D4902) for 3 days, then in differentiation
medium II (differentiation medium I without IBMX and dexamethasone) with medium
change once a week. Mature BAs could be obtained 20–30 days after induction.
Fabricating 3D BA microtissues in microwells
Aggrewells (Stemcell Technologies #34815, #34425) were pre-treated with antiadherence rinsing solution (Stemcell Technologies, #07010) following the manufacturer’s
instruction. Single BAPs were seeded into Aggrewells with differentiation medium I.
Differentiation medium II was used after three days and refreshed once a week.
Differentiated BA microtissues were collected by centrifugation at 100 g for 3 min.

65

Fabricating 3D BA microtissues in shaking plates
Single BAPs were suspended in differentiation medium I in a low adhesion 6-well
plate (Corning, #3471) shaking at 75 rpm. Detailed methods of culturing cells in shaking
plates can be found in our previous publications36–40. Differentiation medium II was used
after three days and refreshed once a week. The plate was tilted and placed in static for 5
min to settle down the microtissues to change medium. 90% of the exhausted medium was
replaced with fresh medium. BA microtissues were collected by pipetting the medium up
and down to suspend the microtissues and spinning at 100 g for 3 min.
Fabricating 3D BA microtissues in thermoreversible hydrogels
Single BAPs were suspended in growth medium I in low adhesion 6-well plate
shaking at 75 rpm overnight to form BAP spheres. The spheres were then mixed with 10%
ice-cold PNIPAAm-PEG (Cosmo Bio, #MBG-PMW20-5005) solution dissolved in
DMEM medium. The mixture was then cast on a tissue culture plate and incubated at 37 °C
for 10 min to form a hydrogel before adding the pre-warmed differentiation medium I.
Differentiation medium II was used after three days and refreshed once a week. To harvest
BA microtissues, the medium was removed, and ice-cold DPBS (Life Technologies,
#21600044) was added to dissolve the hydrogel for 5 min. Finally, BA microtissues were
collected by spinning at 100 g for 3 min. Detailed methods of encapsulating cells in this
thermoreversible hydrogel can be found in our previous publications36,40–44.
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3D microtissues transplantation
The animal experiments were conducted following the protocols approved by the
University of Nebraska–Lincoln Animal Care and Use Committee. 6 mice were used for
each study group. 6-week-old male B6.129S7-Rag1tm1Mom/J or Rag1 knock-out mice
(Rag1-/-) were purchased from Jackson. Mice were transplanted with 1.25 million cells
suspended in DPBS. DPBS was used as a sham control. Briefly, 3D microtissues were
collected and transferred into a sample loading tip bent to have a U-shape. The tips were
connected to a PE50 tube (BD Diagnostics system, #427516), and microtissues were
slowly pushed into the center of the tube using a pipetman. The PE50 tube with
microtissues was then bent into U-shape and placed into a microcentrifuge tube with both
the PE50 tube ends kinked and facing up. The EP tube was centrifuged at 1000 rpm for 10
seconds to pack the microtissues tightly so that the medium was located to the two ends.
The PE50 tube was connected to a loading tip again. Microtissues were slowly pushed to
one end of the PE50 tube using a pipetman. This operation was to remove the medium so
that no medium was injected into the kidney capsule. Otherwise, the medium would wash
out the injected microtissues from the kidney capsule. The right kidney of an anesthetized
mouse was exposed. A small scratch on the flank of the kidney was made by a syringe 25gauge needle, creating a nick in the kidney capsule. Saline was applied with a cotton swab
to keep the kidney wet. The PE50 tube was inserted into the capsule to make a small pocket
under the capsule. Microtissues were slowly pushed into the pocket. The PE50 tube was
carefully retracted, and the nick was cauterized with low heat. After stopping bleeding,
saline was applied, and the kidney was placed back. Details can be found in previous
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publications (Szot, Koudria and Bluestone, 2007; Jofra et al>, 2018). After 18 days of
transplantation surgery, Rag1-/- mice without BA transplantation were fed with NCD
(Research diets, #D12450Ji) or HFD (Research diets, #D12492i) and labeled as Rag1-/NCD and Rag1-/- HFD, respectively. Rag1-/- mice transplanted with BA microtissues were
fed with HFD and labeled Rag1-/- HFD+BA. Wild-type (WT) mice without BA
transplantation were fed with NCD or HFD and labeled as WT NCD and WT HFD.
Immunocytochemistry
Cells cultured on 2D were fixed with 4% paraformaldehyde (PFA) at room
temperature for 15 min, permeabilized with 0.25% Triton X-100 for 10 min and blocked
with 5% donkey serum for 1 h before incubating with primary antibodies (Table S1) in
DPBS + 0.25% Triton X-100 + 5% donkey serum at 4 °C overnight. After washing,
secondary antibodies (Table S1) were added and incubated at room temperature for 2 h
followed by incubating with 10 mM 4',6-Diamidino-2-Phenylindole, Dihydrochloride
(DAPI) for 10 min. Cells were washed with DPBS three times before imaging with a
Fluorescent Microscopy (Zeiss, Germany). For 3D microtissues immunostaining,
microtissues were fixed with 4% PFA at 4 °C overnight. 40 μm thick tissue sections were
obtained via cryosection. The sections were washed with DPBS three times and stained as
the 2D cell cultures.
For in vivo studies, mouse tissues were harvested and fixed with 4% PFA at 4 °C
overnight. 5 μm thick sections were obtained via paraffin-embedding and section. The
sections were deparaffined with xylene three times and rehydrated sequentially in 100%,
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95%, 70%, 50% ethanol, and distilled water. For hematoxylin and eosin (H&E) staining,
rehydrated sections were stained in Mayers Hematoxylin (Ricca Chemical Company,
#3530-16) for 1 min, washed in distill water for 5 times, in DPBS once, and in distilled
water 3 times with 1 min for each wash and stained in Eosin (Fisher, #SE23-500D) for 1
min. The sections were then dehydrated in 95% ethanol (3 times), 100% ethanol (2 times),
and xylene (3 times) with 1 min for each wash before being mounted with coverslips. For
immunostaining, heat-induced epitope retrieval was done on rehydrated tissue sections
using the antigen retrieval buffer (Abcam, #ab93680) following the manufacturer’s
instruction. The sections were stained as the 2D cell cultures.
Flow Cytometry
Cell culture or microtissues were dissociated into single cells with 0.25% trypsinEDTA. Single cells were fixed with 4% PFA and stained with primary antibodies at 4 °C
overnight. After washing (three times) with 1% BSA in DPBS, secondary antibodies were
added and incubated at room temperature for 2 h. Finally, cells were washed with 1% BSA
in DPBS and analyzed using CytoFLEX LX (Beckman Coulter, USA). Isotype controls
served for negative gating.
Serum preparation
Blood samples were collected from the mouse tail. Cells were removed via
centrifugation at 3000 g for 10 min at 4 ºC. The supernatant was transferred into a new
tube and centrifuged at 3000 g for 5 min at 4 ºC to collect the serum.
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Mouse adipokine array and human obesity array
Mice were sacrificed. Blood was collected, and serum was isolated as described
above. 100 µL serum was applied to the mouse adipokine array (R&D systems, #ARY013) following the manufacturer’s instruction. 70 µL serum was applied to the human
obesity array (RayBiotech, #QAH-ADI-3-2) following the manufacturer’s instructions.
Glucose tolerance test (GTT)
Mice were fasted from the morning for 16 h. Glucose (0.75 g/kg body weight) was
administrated via intraperitoneal injection. Blood samples were collected to measure the
glucose level at 0 (baseline), 30, 60, 90, and 120 min after injection.
Insulin tolerance test (ITT)
Mice were fasted overnight for 8 h. Insulin (Sigma, # I9278-5ML, 0.75 U/kg body
weight) was administered via intraperitoneal injection. Blood samples were collected to
measure the glucose level at 0 (baseline), 30, 60, and 90 min after injection.
Body composition
Mouse fat and lean mass were analyzed by Minispec LF50 (Bruker, USA).
Statistical Analysis
The data are presented as the mean ± SEM. Unpaired t-test and one-way analysis
of variance (ANOVA) were used to compare two and more than two groups, respectively.
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Two-way ANOVA was used to compare mice metabolic curves and arrays. P < 0.05 was
considered statistically significant.
Results
Fabricating 3D BA microtissues.
The brown adipose progenitors (BAPs) used in this study were isolated from the
superficial neck fat of a human subject and have been well characterized and documented33.
Like the 2D differentiation, we cultured the microtissues in differentiation medium I for 3
days and then in differentiation medium II with a medium refresh every 7 days (Figure
4.1A). To prepare 3D BA microtissues, single BAPs were placed in microwells
(Aggrewells) in the growth medium. Cells interacted, gradually contracted, and formed
compact spheroids after 24 h (Figure 4.1B). Microtissues grew in size significantly during
the differentiation (Figure 4.1B). For instance, microtissues with an initial diameter of 100
µm became 200 µm on day 17 (Figure 4.1B). The microtissue size growth can result from
the cell number increase due to cell proliferation or the cell size increase, or both. Cell
proliferation and size growth were observed during the differentiation of BAPs to BAs in
2D culture34. When the day 17 microtissues were placed in a conventional tissue culture
plate, they adhered to the surface, and individual cells migrated out (Figure 4.1C, 4.1D).
Immunostaining showed that most of the cells in the microtissues expressed the UCP-1
protein, a biomarker of mature and functional BAs (Figure 4.2A). The attached
microtissues also expressed high level UCP-1 (Figure 4.2B). UCP-1 is a mitochondria
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membrane protein that is critical for non-shivering thermogenesis. BAT dissipates energy
in the form of heat via the UCP-1 activity47,48.
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Figure 4.1. Fabricating BA microtissues. (A) BA differentiation protocol. (B) Preparing BA microtissues in
microwells. Phase images day-27 BA microtissues after plating on 2D surface for 3 days (C) and 9 days (D).
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Figure 4.2. 3D culture enhanced BA differentiation. (A) 3D BA microtissues in microwells on day 17 and
their immunostaining. HuNu: human nuclear antigen. (B) The day 17 BA microtissues were plated on 2D
surface for 6 days and stained for UCP-1 expression. (C) Flow cytometry analysis of UCP-1 expression on
day 17 for BAs prepared in 2D culture and 3D culture with varied aggregate sizes. (D) The mean fluorescent
intensity (MFI) of UCP-1 as measured with flow cytometry in (C). Data are represented as mean ± SEM
(n=3). ****p < 0.0001.

74

To study if the microtissue size influences the differentiation efficiency, we
prepared microtissues with a diameter of 100, 250, and 450 µm (initial diameter) and
differentiated them. All microtissues grew in size significantly (Figure 4.3). While the 100
and 250 µm microtissues maintained spherical, the 450 µm microtissues gradually became
non-spherical (Figure 4.3D). Cell death (Figure 4.3D, red arrows) and fusion between
microtissues (Figure 4.3D, blue arrows) were observed only in the 450 µm microtissues.
On day 17, flow cytometry analysis showed 92.6%, 72.6%, and 80.4% of the cells in the
100, 250, and 450 µm microtissues were UCP-1 positive. For comparison, 2D culture
resulted in 78.8% UCP-1 positive cells (Figure 4.2C). The mean fluorescent intensity (MFI)
of UCP-1 intensity in 100 µm microtissues is significantly higher than in other groups
(Figure 4.2D). The results show that a 3D microenvironment promoted brown
adipogenesis and UCP-1 expression. However, a small microtissue size should be used to
maximize the benefits. We used 100 µm microtissues for the rest of the study.
The cells migrated from microtissues had the classical BA characteristics (Figure
4.4). They expressed a high level of UCP-1 protein (Figure 4.2A-C, 4.4D) and had
multiple small oil droplets (Figure 4.1C, 4.4A-C) and a high mitochondrial content
(Figure 4.4C). In addition, they expressed the typical BA marker genes at high levels
(Figure 4.4E).
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Figure 4.3. Preparing BAs in 2D culture (A) or microwells with varied aggregate sizes (B, C, D). Day 9 and
Day 17 microtissues were released from microwells before imaging.
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Figure 4.4. Characterization of BA microtissues. BAs prepared in 3D had typical BA phenotypes such as large
numbers of small lipid droplets (A, B), abundant mitochondria (C) and UCP-1 proteins (D). They expressed
BA-specific genes at high level (E). WA and BA: adipocytes differentiated from human WAPs and BAPs in
microwells. TMRM: Tetramethylrhodamine, methyl ester (mitochondrial probe). Data are represented as mean
± SEM (n=3). ***p < 0.001, ****p < 0.0001 ***p < 0.001
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BA microtissues survived in vivo with angiogenesis and innervation.
As said, very few BAT transplantation studies used T2DM mice. To fill the gap,
we used high fat diet (HFD)-induced OB and T2DM mouse model to test the engineered
BA microtissues. We selected the immune-deficient Rag1-/- mice as recipients since they
tolerate xenogeneic and allogeneic tissues and have HFD-induced OB and metabolic
disorders49,50. In addition, they developed diabetes when given STZ51. Rag1-/- mice fed with
normal chow diet (NCD) and HFD with no microtissue transplantation were used as
positive and negative controls to evaluate the microtissue efficacy. Wild type (WT) mice
fed with NCD and HFD were also included to assess the difference of response to HFD
between WT and Rag1-/- mice. HFD was initiated 18 days post-transplantation (Figure
4.5A). A significant number of adipose tissues was found in the kidney capsule 1 month
and 5 months after transplantation (Figure 4.5B). H&E staining showed the dense kidney
tissue and the adjacent adipose tissue with large amounts of oil droplets (Figure 4.5B). The
oil droplets were bigger in the 5 month sample. No tumor or non-adipose tissues were
found in the transplants, indicating safety of fully differentiated BAs in vivo.
The oil droplets were much bigger than those of the endogenous BAT (endoBAT)
of NCD fed mice, but comparable to the endoBAT of HFD fed mice (Figure 4.7A), which
indicates whitening of the transplanted BAs. However, a high level of UCP-1 protein was
observed (Figure 4.5C), showing the BA function was maintained for at least 5 months.
Host blood vessels grew into the transplants (Figure 4.5D). The vessel density was lower
than the endoBAT of NCD mice but comparable to the endoBAT of HFD mice (Figure
4.7D). Innervation is critical for BA function. Tyrosine hydroxylase (TH+) nerves were
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found in the transplants (Figure 4.5E), and their density was lower than this of the NCD
mouse endoBAT but comparable to the density in the HFD mouse endoBAT (Figure 4.7E).
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Figure 4.5. BA microtissues survived in vivo with angiogenesis and innervation. (A) The transplantation
protocol. (B) H&E staining of 1-month and 5-month transplant. The transplant and adjacent kidney tissue
are labelled. Immunostaining of the 5-month transplant and adjacent kidney tissue with human UCP1
(hUCP1) (C), mouse CD31 (mCD31) (D) , and mouse tyrosine hydroxylase (mTH) (E) .
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BA microtissues alleviated obesity and diabetes.
We regularly measured the body weight, fat and lean mass, plasma glucose level,
glucose tolerance, and insulin sensitivity (Figure 4.6). To mimic the β cell dysfunction of
T2DM, we injected low-dose STZ (90 mg/kg) after 3-month HFD. The bodyweight drops
and the fasting glucose level rise after the STZ injection indicated the progression of T2DM
(Figure 4.6A, 4.6D). There was no significant difference in total diet intake between the
HFD groups. Under HFD, both WT and Rag1-/- mice developed OB (Figure 4.6A) and
grew large fat masses (Figure 4.6B, 4.6C). We found Rag1-/- mice were slightly more
prone to HFD-induced OB and metabolic disorders but were suitable for our studies. The
transplant significantly reduced the body weight gain, fat content, and fasting glucose level
while increasing insulin sensitivity and glucose tolerance (Figure 4.6).
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Figure 4.6. BA microtissues alleviated obesity and diabetes. (A) Body weight gain, (B) % fat mass, (C) %
lean mass, (D) fasting glucose level, (E) GTT (day 150), and (F) ITT (day 170). WT: wild type mouse; Rag1/: Rag1 knock-out mice; NCD: normal chow diet; HFD: high fat diet. Data are represented as mean ± SEM
(n=6). *p < 0.05, ***p < 0.001, ****p < 0.0001.
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BA microtissues prevented the whitening of endogenous BATs.
The endoBAT was whitened in Rag1-/- mice fed with HFD, as shown by an increase
of adipocyte size and oil droplets (Figure 4.7A-C), and a reduction of the mUCP-1 protein
expression (Figure 4.7D), blood vessel density (Figure 4.7D, 4.7E) and TH+ nerve density
(Figure 4.7E). The transplanted BA microtissues almost wholly prevented the whitening
of endoBAT (Figure 4.7A-E). HFD mice with BA microtissues had similar BA
morphology, blood vessel, and nerve densities to the NCD mice.
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Figure 4.7. BA microtissues protected endogenous BAT (endoBAT). (A) H&E staining of endoBAT. BA
size (B) and area (C) in endoBAT. (D) Mouse UCP-1 and CD31 expression in endoBAT. (E) Mouse TH and
CD31 expression in endoBAT. Data are represented as mean ± SEM (n=6). ****p < 0.0001.
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BA microtissues alleviated endogenous WAT hypertrophy and liver steatosis.
The adipocyte and oil droplet size of subcutaneous WAT (scWAT) was increased
by the HFD. BA microtissues significantly reduced the adipocyte and oil droplet size
(Figure 4.8A-C). CD31 staining showed fewer blood vessels in HFD fed mice. BA
microtissues increased the blood vessel density in HFD fed mice (Figure 4.8D). The liver
fat content was significantly increased in HFD mice but was almost normalized by BA
microtissues (Figure 4.8E). These results showed that the transplanted microtissues had a
profound effect on multiple organs.
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Figure 4.8. BA microtissues reduced endogenous WAT hypertrophy and liver steatosis. (A) H&E staining
of mouse subcutaneous white adipose tissue (scWAT). (B, C) Adipose size and area in scWAT. (D) Mouse
CD31 expression in scWAT. (E) H&E staining of mouse liver. (F) Adipose area in liver. Data are represented
as mean ± SEM (n=6). *p < 0.05, **p < 0.01, ****p < 0.0001.
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BA microtissues secreted soluble factors and modulated endogenous adipokines.
We used a Human Obesity Antibody Array to measure human protein factors in the
blood. We found that the concentrations of human adiponectin, chemerin, and TGF-β1 in
mice with transplants were significantly higher than background (Figure 4.9A), indicating
the transplanted BAs were secreting soluble factors. Research has shown that adiponectin
secreted by white and brown adipocytes has a protective role in obesity-associated
metabolic and cardiovascular diseases. Adiponectin influences multiple tissues such as the
liver, skeletal muscle, and vascular system. Adiponectin can increase insulin sensitivity52,53,
suppress inflammation, and reduce atherosclerosis54–56. Plasma adiponectin level is
negatively correlated with obesity, and adiponectin deficiency enhances HFD induced
insulin resistance57. Chemerin plays a positive role in the metabolic health58,59. TGF-β1 is
a mediator of insulin resistance in metabolic disease60,61.
We also used a Mouse Adipokine Antibody Array to measure 38 obesity-related
mouse molecules. The levels of Adiponectin, ANGPT-L3, C-reactive protein, ICAM-1,
IGFBP-3, IGFBP-5, IGFBP-6, Lipocalin-2, and Pentraxion2 were significantly reduced,
and the IGF-1 concentration was increased by the HFD (Figure 4.9B, 4.9C). All of these
molecules were normalized by the transplanted BA microtissues (Figure 4.9C). Thus, the
transplanted microtissues had a significant effect on the endogenous adipokines.
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Figure 4.9. BA microtissues secreted human protein factors and modulated endogenous adipokines. (A) Protein
factors in mouse plasma detected using human obesity antibody array. (B, C) Heatmap and quantification of
adipokines in mouse plasma detected using mouse adipokine antibody array. Data are represented as mean ±
SEM (n=3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Scale up BA microtissues production.
All the above experiments used microwells to prepare microtissues. However,
microwells are unsuitable for producing microtissues at large scales, which are needed for
future extensive animal studies, drug screens, and clinical applications. Previously, our lab
used 3D suspension culture (e.g., shaking plates, spinning flasks, stirred tank bioreactors)
to prepare human pluripotent stem cells at large scales36–40. We also pioneered in culturing
stem cells at high density in thermoreversible PNIPAAm-PEG hydrogels36,40–44,62. We
found that BA microtissues could be prepared in both systems (Figure 4.10). Large tissue
aggregates formed via fusion of multiple microtissues were found in shaking flasks (Figure
4.10A), while microtissues in PNIPAAm-PEG hydrogels were uniform (Figure 4.10B).
BAs from both systems expressed a high level of UCP-1 protein (Figure 4.10C). Thus,
both systems can be used to scale up the microtissues production.
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Figure 4.10. Scaling up BA microtissue production. Preparing BA microtissues in shaking plates (A) and
PEG hydrogel (B). (C)Immunostaining of day 17 BA microtissues prepared in shaking plates and PEG
hydrogel. Microtissues were plated on 2D surface for 6 days before staining.
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Preserving BA microtissues.
Lastly, we evaluated if BA microtissues could be preserved. Microtissues preserved
in cell culture medium at room temperature for 24 h (Figure 4.11B) had similar viability
to the fresh sample (Figure 4.11A). Microtissues could also be cryopreserved in liquid
nitrogen for the long term without significantly sacrificing cell viability (Figure 4.11C).
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Figure 4.11. Preserving BA microtissues. Live/dead cell staining of day 27 fresh BA microtissues (A) or
stored at room temperature for 24 h (B) or stored in liquid nitrogen and recovered (C).

94
Table 4.1, Antibodies used in chapter 4.
Antibody
Anti-UCP1
Tyrosine Hydroxylase (TH)
CD31
Anti-UCP1
Anti-Human Nuclear
Antigen antibody [235-1]

Supplier
abcam
Fisher scientific
abcam
abcam

Catalog. No
ab155117
AB152MI
ab24590
ab23841

Host species
Rabbit
Rabbit
Mouse
Rabbit

Dilution
1:50
1:50
1:250
1:250

abcam

ab191181

Mouse

1:100

Secondary Antibody
Secondary Antibody

Thermo Fisher
Thermo Fisher
Jackson Immuno
Research Labs
Jackson Immuno
Research Labs

A-21202
A-21207

Donkey
Donkey

1:500
1:500

715585150

Donkey

1:500

711545152

Donkey

1:500

Secondary Antibody
Secondary Antibody

Table 4.2. One-way ANOVA multiple comparisons test results of mean UCP-1 intensities for day 17 BA in
Figure 4.2D. Data are represented as mean ± SEM (n=3). *p < 0.05 , ****p < 0.0001.

Control
2D BA
100 µm
250 µm
450 µm

Control

2D BA

100 µm

250 µm

****
****
****
****

****
****
****

****
****

*

450 µm

Table 4.3. Two-way ANOVA multiple comparisons test results of body weight gain in Figure 4.6.
Tukey's multiple comparisons
test (weight)
WT NCD
WT NCD
WT HFD
****
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

****

****

****

****

****

ns

****

****

Table 4.4. Two-way ANOVA multiple comparisons test results of body fat mass in Figure 4.6.
Tukey's multiple comparisons
test (fat mass)
WT NCD
WT NCD
WT HFD
****
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

****

****

****

****

****

ns

****

****
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Table 4.5. Two-way ANOVA multiple comparisons test results of body lean mass in Figure 4.6.
Tukey's multiple comparisons
test (lean mass)
WT NCD
WT NCD
WT HFD
****
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

****

****

***

****

****

ns

****

***

Table 4.6. Two-way ANOVA multiple comparisons test results of fasting glucose in Figure 4.6.
Tukey's multiple comparisons
test (fasting glucose)
WT NCD
WT NCD
WT HFD
ns
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

ns

****

**

****

**

ns

ns

*

Table 4.7. Two-way ANOVA multiple comparisons test results of GTT in Figure 4.6.
Tukey's multiple comparisons
test (GTT)
WT NCD
WT NCD
WT HFD
ns
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

ns

****

****

****

**

ns

ns

****

Table 4.8. Two-way ANOVA multiple comparisons test results of ITT in Figure 4.6.
Tukey's multiple comparisons
test (ITT)
WT NCD
WT NCD
WT HFD
ns
-/-

Rag1 NCD
-/-

Rag1 HFD
-/-

Rag1 HFD+BAT

WT HFD

-/-

-/-

-/-

Rag1 NCD Rag1 HFD Rag1 HFD+BA

ns

ns

*

ns

***

ns

ns

ns

*
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Table 4.9. Two-way ANOVA multiple comparisons test results of mouse adipokine antibody array in Figure
4.9C.
-/-

Adiponectin
ANGPT-L3
C-Reactive
Protein
ICAM-1
IGF-I
IGFBP-3
IGFBP-5
IGFBP-6
Lipocalin-2
Pentraxin 2

-/-

-/-

-/-

-/-

Rag1 NCD vs. Rag1
HFD
****
*

Rag1 NCD vs. Rag1
HFD+BA
ns
ns

Rag1 HFD vs. Rag1
HFD+BA
**
*

*
*
***
****
ns
*
**
ns

ns
ns
ns
ns
ns
ns
ns
ns

***
***
***
****
*
*
**
*

-/-
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Discussion
Our study showed that human BAPs could be differentiated into mature BAs in 3D
to prepare injectable BA microtissues (Figure 4.1, 4.2, 4.3). The 3D culture promoted BA
differentiation and UCP-1 protein expression. BA microtissues could survive in vivo for
the long term with angiogenesis and innervation (Figure 4.5). They alleviated the body
weight and fat gain and improved glucose tolerance and insulin sensitivity significantly in
HFD-induced OB and diabetic mice (Figure 4.6). The transplanted BA microtissues
impacted multiple tissues such as endogenous BAT, WAT, and liver (Figure 4.7, 4.8). In
addition, they secreted protein factors and influenced the secretion of endogenous
adipokines (Figure 4.9). These microtissues could be produced using the scalable 3D
suspension culture or in a PEG hydrogel (Figure 4.10) and could be cryopreserved and
shipped at room temperature (Figure 4.11). To our best knowledge, this is the first report
on engineering human BA microtissues and showing their safety and efficacy in OB and
T2DM mice. The findings that 3D culture promotes BA differentiation and the microtissue
size affects the differentiation are all new.
To date, most BAT transplantation studies used mouse BATs. There is a need to
study if human BAT can manage OB and its associated metabolic disorders. The Tseng
group isolated and immortalized human BAPs and demonstrated that these cells could
differentiate into mature BAs in vivo and reduce the HFD-induced OB and metabolic
symptoms32,33. They transplanted proliferating BAPs instead of mature BAs that have
exited the cell cycle. The possible reason is that BAPs have a better survival rate in vivo.
A recent study showed that about 12.1% of immortalized mouse BAPs survived in SCID
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mice 7 days after transplantation with Matrigel, while only 2.7% of mature BA
(differentiated from BAPs in vitro) were live after 7 days using the same transplantation
procedure18. Consequently, only BAPs showed an efficacy in vivo18. However, there are
potential problems with using BAPs. First, the differentiation efficiency in vivo is typically
low18. Second, proliferating cells have a higher tumorigenic risk, especially for
immortalized cells. Transplanting fully differentiated BAs has advantages in that they can
be prepared in vitro at high purity (e.g., ~93% in this study) (Figure 4.2). They are less
likely to have uncontrolled growth in vivo. However, approaches must be developed to
improve their survival rate in vivo and avoid cell death during the harvest in vitro, as found
in our preliminary studies.
Prior studies showed transplanting mouse BATs prevented/reversed OB and its
associated metabolic disorders. It should be noted that only transplanting intact 3D BAT,
not dissociated single BAs, achieved long-term survival and function17–20, indicating that
3D BAT, not single BAs, should be used as therapeutics in the future. Researchers typically
inject cultured BAPs with Matrigel to mimic a 3D tissue. Matrigel can both restrict the
cells at the transplantation size and enhance their survival18. However, Matrigel is extracted
from mouse tumor tissue and is not chemically defined, and not compatible with clinical
applications. Our preliminary study showed that a large percentage of mature BAs died
during the harvest process, suggesting that single BAs are unsuitable for transplantation.
Our engineered BA microtissues are injectable, do not need extra matrix and dissociation,
thus addressing all these problems.
Interestingly, we found that the microtissue size influenced the BA differentiation
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efficiency significantly. The optimal diameter is about 100 µm (initial diameter). BAs have
a high demand for glucose, oxygen, and nutrients to meet their high metabolic activities.
BAs have a high demand for glucose, oxygen, and nutrients to meet their high metabolic
activities18,63–67. Nutrients are transported in these microtissues mainly through diffusion.
Therefore, cells at the center of large microtissues may not have a sufficient supply of
nutrients, negatively affecting the differentiation process. A second possible cause is that
cells secrete autocrine or/and paracrine factors are important to BA differentiation. The
microtissue diameter influences the concentrations and gradients of these factors. The exact
reason should be made clear in future studies.
We demonstrated that the production of BA microtissues could be scaled up using
the 3D suspension culture or a 3D thermoreversible hydrogel matrix. A limitation with the
3D suspension culturing is that the microtissues are heterogeneous in size (Figure 4.10A).
Using the thermoreversible hydrogel matrix can produce homogenous microtissues in size
(Figure 4.10B). However, the matrix is expensive. Our group recently developed a novel
microbioreactor termed AlgTubes, in which cells are cultured in alginate hydrogel
microtubes37,38,68–73. AlgTubes are scalable and have low cost. The cell aggregate size can
be precisely controlled by the hydrogel tubes. AlgTubes can produce up to 5x108 cells per
mL of culture volume, about 200 times more than the 3D suspension culture. Future studies
can apply AlgTubes to produce fibrous BA microtissues with uniform and precise size at
high density.
BAT is among the most vascularized tissues in the body, averaging ~1.2 capillaries
per BA (versus only ~0.4 capillaries per white adipocyte) 63–67. A substantial blood supply
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is required to provide glucose, fatty acids, nutrients, and oxygen to fuel thermogenesis and
rapidly distribute heat throughout the body

74

. Vascular cells also produce soluble and

insoluble factors critical for BA functions and homeostasis; conversely, BAs produce a
range of growth factors and cytokines that collectively modulate vascular growth, survival,
remodeling, regression, and blood perfusion 65,67,75. In obese mice, the capillary density in
BAT decreases significantly (i.e., ~0.5 capillaries per BA) (Figure 4.7), resulting in
hypoxia and BAT degeneration66. Our results showed that transplanted BA microtissues
prevented the whitening of endogenous BAT (Figure 4.7), which may contribute to the
improvement of glucose and insulin homeostasis. In addition, we showed transplanted BAs
secreted human adipokines (Figure 4.9A) and altered the expression levels of many
endogenous adipokines (Fig 4.9B, 4.9C). Thus, the transplanted microtissues function at
least partially via the endocrine mechanism.
We found that the transplanted microtissues gradually became white adipocyte-like
in morphology (Figure 4.5B), although UCP-1 proteins are still expressed at a high level
(Figure 4.5C). A reason for this whitening is the insufficient vascularization in the
transplant. This agrees well with literature findings that the transplants had fewer blood
vessels than endogenous BAT

18,32

. Consequently, BAs gradually decreased UCP-1

expression and became WAT-like features (i.e., whitening). There are two potential ways
to address this problem. First, as shown in a published study18, supplementing vascular
endothelial growth factor (VEGF) to the transplant can significantly improve its
engraftment, angiogenesis, and function. Second, endothelial cells can be included in the
BA microtissues. As stated in the above paragraph, endothelial cells or vasculature are
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indispensable for BAT in vivo.
We used immortalized BAPs to prepare mature BA microtissues. No tumor or
abnormal tissue growth was observed (Figure 4.5), indicating fully differentiated BAs are
safe in vivo. Thus, it is applicable to isolate and immortalize BAPs from a patient and
expand them to prepare BA microtissues for personalized BA augmentation therapy. An
alternative approach is to prepare induced pluripotent stem cells (hiPSCs) for a patient.
hiPSCs can be generated by reprogramming somatic cells76–78. They have unlimited
proliferation capability and can be differentiated into all types of somatic cells.
Additionally, the transplant’s immune rejection can be avoided by preparing BAT from
personalized hiPSCs79,80. Recent clinical studies showed autologous hiPSCs-derived
dopaminergic neurons, and retinal cells were safe and effective in treating Parkinson’s 81
and macular degeneration80, respectively, indicating the coming of the hiPSCs-based
personalized medicine era. Alternatively, universal hiPSCs can be engineered, for instance,
via inactivating major histocompatibility complex (MHC) class I and II genes and
overexpressing CD47 or/and PD-L181–84. The derivatives of universal hiPSCs are
hypoimmunogenic and can be prepared at large scales as “off-the-shelf” allogeneic
products. hiPSCs have been successfully differentiated into BAs that are metabolically
active in vitro and in mice models35,85–90. Therefore, future studies can explore using
hiPSCs to prepare personalized BA microtissues.
Conclusion
In summary, our study showed that 3D BA microtissues could be fabricated at large
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scales, cryopreserved for the long term, and delivered via injection. BAs in the microtissues
had higher purity, and higher UCP-1 protein expression than BAs prepared via 2D culture.
In addition, 3D BA microtissues had good in vivo survival and tissue integration and had
no uncontrolled tissue overgrowth. Furthermore, they showed good efficacy in preventing
OB and T2DM with a very low dosage compared to literature studies. Thus, our results
show engineered 3D BA microtissues are promising anti-OB/T2DM therapeutics. They
have considerable advantages over dissociated BAs or BAPs for future clinical applications
in terms of product scalability, storage, purity, quality, and in vivo safety, dosage, survival,
integration, and efficacy.
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CHAPTER 5.

SCALABLE CULTURE OF MYOCYTES IN ALGINATE
HYDROGEL MICROTUBES

Introduction
Based on the Food and Agriculture Organization (FAO) data, the global population
is expected to reach 9 billion by 2050. Accordingly, 70% more food will be needed to feed
this population. Meat is a significant part of human food1. Currently, meat is obtained from
natural animals or livestock raised through traditional farms or modern factories2–4. The
natural supply is clearly limited. Livestock farming requires large amounts of water and
land and will reach a limitation. Additionally, farming causes significant environmental
and animal welfare issues5,6. Therefore, alternative approaches that can produce meat in an
efficient and environmentally friendly way are highly wanted.
One option is to produce meat via cell culture7–9. Briefly, animal cells are expanded
to generate large numbers and differentiated into myocytes that are assembled into muscle
tissues. This approach is currently at the proof-of-concept stage. A few significant
technological challenges must be addressed for its further advance. One of these challenges
is to produce cells at large scales in a cost-effective way. Tons of cell mass will be needed
per day for meat production. None of the current cell culture technologies, e.g., 2dimensional (2D) flasks and stirred tank bioreactors (STRs), can achieve this scale and
price. For instance, STRs can only produce ~2x106 cells/mL. This cell mass occupies ~0.4%
of the culture volume. Growing>1011 cells/batch with STRs is still difficult.
Previously, our lab developed a new cell culture system termed AlgTubes10–17. With
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this method, cells are cultured in hollow, microscale alginate hydrogel tubes. AlgTubes
provide a cell-friendly microenvironment, resulting in paradigm-shifting improvements in
cell viability, growth rate, yield, culture consistency, scalability. When culturing human
stem cells and adult cells, we have achieved up to 5x108 cells/mL volumetric yield, which
is ~250 times the current-state-of-the-art. AlgTubes make large-scale cell production
feasible. For instance, to produce 1012 cells from 1x107 cell seeds, our modeling shows that
AlgTubes (vs. the current stirred tank bioreactors) reduce the culture volume from 1365 to
4.0 litters, culture time from 40 to 20 days, and passaging operations from 9 to 1,
collectively reducing the production cost and increasing the production capability in a
significant manner. Thus AlgTubes have huge potential for culturing animal cells for meat
production. In this work, we systematically re-engineered the AlgTubes and studied
culturing animal myoblasts to produce meat.
Materials and Methods
Cell lines and Materials
Mouse bone marrow mesenchymal stem cell line (D1, CRL-12424), mouse
myoblast cell line (C2C12, CRL-1772), quail myoblast cell line (QM7, CRL-1962), mouse
beige adipocyte cell line (X9, CRL-3282), mouse fibroblast cell line (3T3, CRL-1658)
were purchased from ATCC and maintained as instructed by ATCC. Briefly, C2C12, D1,
and 3T3 were cultured in DMEM supplemented with 10% FBS. QM7 were cultured in
medium 199 supplemented with 10% TPB and 10% FBS. X9 were cultured in DMEM/F12
supplemented with 15% FBS and 2.36 mM L-glutamine. All cell culture medium was
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refreshed every 2-3 days. To induce C2C12 and QM7 myotube formation, the culture
medium was supplemented with 10% horse serum instead of fetal bovine serum.
Additionally, the following chemicals and reagents were also used for the project:
sodium alginate (cat # 194-13321, 80~120cp, Wako Chemicals), sodium hyaluronate: (cat
# HA 700K-5, Lifecore Biomedical), tryptose phosphate broth (TPB, cat # 18050039, Life
Technologies), Dulbecco's Modified Eagle's Medium (DMEM, cat # 30-2002, ATCC),
Medium 199 with Earle's BSS (cat # 12119F, Lonza), DMEM/F12 (cat # 30-2006, ATCC),
Fetal Bovine Serum (FBS, cat # 10437028, Gibco), L-Glutamine (cat # 25030081, Gibco),
propidium iodide (cat # 195458, MP Biomedicals, LLC), Vybrant multi-color cell-labeling
kit (cat # V22889, Molecular Probes), MF20 antibody (cat # MAB4470, R&D systems),
RGD peptide (Genscript), Alginate Lyase (cat # A1603, Sigma).
Modifying Alginates with RGD peptides
2% alginate was dissolved in 0.1N NaOH and reacted with DVS (1:3 molar ratio
between OH group and DVS) for 14 minutes. 20% to 30% of the OH groups in alginate
polymers were modified with DVS. Dialysis was done to remove excessive DVS. The
RGD peptide containing cysteine was used to react with alginate-vs under the alkaline
condition to make alginate-RGD. 10% of the modified OH groups were reacted with RGD
peptides. Alginate-RGD were mixed with unmodified alginate to make a 2% alginate
solution with 1 mM RGD concentration.
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Processing alginate-RGD hydrogel tubes (AlgTubes)
A custom-made micro-extruder was used to process AlgTubes. A hyaluronic acid
(HA) solution containing single cells and an alginate-RGD solution are pumped into the
central and side channel of the micro-extruder, respectively, to form coaxial core-shell
flows that are extruded into a CaCl2 buffer (100mM) to make AlgTubes. Subsequently,
CaCl2 buffer was replaced by cell culture medium. Detailed methods of culturing cells in
alginate hydrogel tubes can be found in our previous publications10–16.
Culturing cells in AlgTubes
For typical cell culture, 20 µL of cell solution in AlgTubes were suspended in 3 mL
medium in a 6-well plate. Cells were seeded at the density of 1-2x106 cells/mL hydrogel
tube space. 2% alginate modified with 1 mM RGD peptide was used. The hydrogel tube
diameter was 200 – 300 µm with shell thickness around 30-70 µm. To passage cells, the
medium was removed, and alginate hydrogels were dissolved with 0.5mM EDTA and 100
µg/ mL alginate lyase for 10 min at 37 ºC. Cell mass was collected by centrifuging at 100
g for 5 min and treated with 0.25% trypsin-EDTA at 37 ºC for 10 min and dissociated into
single cells. Digestion was neutralized by complete cell culture medium.
Immunocytochemistry
Cells cultured on 2D were fixed with 4% paraformaldehyde (PFA) at room
temperature for 15 min, permeabilized with 0.25% Triton X-100 for 10 min, and blocked
with 5% donkey serum for 1 h before incubating with primary antibodies in DPBS + 0.25%
Triton X-100 + 5% donkey serum at 4 °C overnight. After washing, secondary antibodies
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were added and incubated at room temperature for 2 h followed by incubating with 10 mM
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) for 10 min. Cells were washed
with DPBS three times before imaging with a Fluorescent Microscopy. For 3D fibrous cell
mass immunostaining, cell mass was fixed with 4% PFA at 4 °C overnight. 40 μm thick
tissue sections were obtained via cryosection. The sections were washed with DPBS three
times and stained as the 2D cell cultures. Alternatively, the cell mass was directly incubated
with primary antibody at 4 ºC for 48 h after fixed and wash. After extensive wash,
secondary antibody was added and incubated at 4 ºC for 24 h followed by incubating with
10 mM DAPI for 10 min and imaged with a Fluorescent Microscopy.

Statistical analysis
The data are presented as the mean ± SEM. We used one-way ANOVA to compare
all groups. P < 0.05 was considered statistically significant.
Results
The engineered Alginate-RGD culture system (AlgTubes)
We modified our alginate hydrogel tubes (AlgTubes) with RGD peptides so that
anchor-dependent myoblasts could be cultured in AlgTubes. Briefly, the sodium alginate
was dissolved in 0.1 N NaOH and reacted with DVS through “click” chemistry to generate
VS groups on the alginate polymers18. The RGD peptides with free -SH groups then reacted
with these VS groups via Michael addition reaction. Alginate-RGD was mixed with
unmodified alginate to produce a 2% alginate solution with 1 mM RGD concentration,
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used to process AlgTubes. A cell solution and the 2% alginate-RGD solution were pumped
into the central and side channel of a custom-made micro-extruder, respectively, to form a
coaxial core-shell flow extruded through a nozzle and into a CaCl2 buffer (100 mM)
(Figure 5.1A and 5.1B). The shell alginate flow was crosslinked by Ca2+ ions in seconds
to form an alginate hydrogel tube. Subsequently, cells were grown in the tubes suspended
in the cell culture medium in a 6-well plate.
The AlgTubes system is designed to provide cells with a friendly microenvironment
(Figure 5.1C). First, RGD peptides allow cells to attach to a substrate and proliferate.
Second, oxygen, nutrients, and macromolecules (with Mw up to 700 kDa) can freely and
quickly diffuse through the hydrogel shell. Third, the hydrogel tubes direct cell expansion
axially while confining the radial diameter of cell masses within the diffusion limit (~400
μm) to ensure efficient mass transport during the whole culture period. As shown in our
previous research, the diffusion limit in 3D human cell culture is typically less than 500
µm10–17. Forth, the hydrogel tubes also isolate hydrodynamic stresses from cells. Lastly,
the tubes provide free and uniform 3D microspaces that allow cells to interact with each
other and grow (Figure 5.1C).
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Figure 5.1. Overview of culturing cells in alginate hydrogel tubes (AlgTubes). (A, B) Process AlgTubes. A
cell suspension and an alginate solution is pumped into the central channel and side channel of the
microextruder, respectively, to form a coaxial coreshell flow that is extruded through the nozzle into the
CaCl2 buffer. The shell alginate flow is crosslinked by Ca

2+

ions to form an alginate hydrogel tube within

seconds. (C) Illustration of cell microenvironment of AlgTubes.
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C2C12 expansion in AlgTubes
We cultured C2C12 in AlgTubes for 19 days (Figure 5.2). Day 0 image showed
our seeding density was very low (1x106 cells/mL hydrogel tube spaces). Only a few cells
could be found in the amplified image on day 0. A low cell seeding density allows a large
expansion fold per passage and is wanted for industrial cell production. After 24 hours,
almost all cells attached to the hydrogel tube inner surface with no or minor cell death. On
day 4, cells expanded significantly and formed a confluent monolayer. On day 7, multilayer
cell masses were seen (green arrows). The dark-field image on day 7 showed white cell
mass (orange arrows), indicating 3D multilayer cell masses. After 14 days, the dark-field
images show extensive 3D white cell masses (yellow arrows), and myotubes could be
found in phase images (blue arrows). We found that some locations of the tubes were bent
(Figure 5.2A, red arrows) after 14 days, indicating the myotube contraction force was more
significant than the hydrogel elasticity. AlgTubes with stronger Young’s modulus can
overcome this problem to further enhance the cell culture outcome in the future. The
modulus can be increased by increasing the alginate concentration or using high molecular
weight alginate or thicker shells.
Live/Dead cell staining of the cell fibers on day 19 showed most cells were live
cells, and a few dead cells were detected, indicating high viability of C2C12 cultured in
AlgTubes after 19 days (Figure 5.3A). We counted the cells using Countless II cell counter.
The cell quantification shows that C2C12 cells reached ~6.4x107 and ~1.1x108 cells/mL
hydrogel tubes space on day 10 and day 19, respectively (Figure 5.3B). The released day
19 cells had healthy morphology. There were some large cell aggregates (Figure 5.3C,
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green arrows), which might be the contracted myotubes. Immunostaining on myofiber
(MF20) confirmed the existence of myotubes (Figure 5.3C). Our results agree with the
literature findings that C1C12 cells spontaneously differentiate to form myotubes at high
density even in the expansion medium.

Figure 5.2. C2C12 expansion in AlgTubes. (A) Phase or dark-field pictures of C2C12 cells in AlgTubes on
different days. Green arrows: multilayer cell masses; yellow arrows: 3D white cells mass; blue arrows:
myotubes; red arrows: bent tubes.
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Figure 5.3. Viability and quantification of C2C12 expansion in AlgTubes. (A) Live/Dead cell staining of
C2C12 in AlgTubes on day 19. (B) C2C12 quantification on day 0, day 10 and day 19. (C) Single C2C12
cells released from Alg-RGD-Tubes on day 19 and stained with MF20 and PI. Green arrows: myotubes.
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C2C12 differentiation in AlgTubes
C2C12 cells were expanded for 7 days in AlgTubes before initiating differentiation
(Figure 5.4). Cells formed 3D cell masses with the differentiation protocol, indicating that
cells maintained proliferation during the differentiation process. Myotubes could be seen
after six days of differentiation (Figure 5.4A, blue arrows). Most cells were live based on
the Live/Dead cell staining assay (Figure 5.4B). After differentiation for 12 days, the
volumetric yield reached ~1.2x108/mL (Figure 5.7C).

We used immunostaining to

evaluate the formed myotubes (Figure 5.5). The staining confirmed the 3D cell masses in
the hydrogel tubes. There was still some space at the tube core (Figure 5.5B and 5.5D).
Smaller tubes can be used in the future. A large percentage of cells were MF20 positive
(Figure 5.5A and 5.5B). The myotubes were large and aligned along the hydrogel tubes.
Most cells expressed MyoD and PAX7, indicating the cell renewal was repressed, and
muscle differentiation was promoted (Figure 5.5C and 5.5D).
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Figure 5.4. C2C12 differentiation in AlgTubes. C2C12 were cultured for 7 days in alginate tube before
differentiation. (A) Phase or dark-field pictures of C2C12 differentiation in AlgTubes on different days. (B)
Live/Dead cell staining on day 19. Blue arrows: Myotubes

127

Figure 5.5. Immunostaining of C2C12 expanded for 7 days and differentiated for 12 days in AlgTubes. Cell
fibers were fixed, cryosection and stained with myofiber (MF20) and DPAI (A, B), and stained with MyoD
and PAX7 (C, D).
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C2C12 and D1 co-culture and differentiation
Our previous research found that mesenchymal stem cells (MSCs) or fibroblasts
could significantly improve cell viability in high density cell culture. We thus did a coculture experiment to evaluate if mouse MSCs (D1 cells) could boost the growth rate and
yield of C2C12 in AlgTubes (Figure 5.6). D1 cells were pre-stained with vibrant celllabeling DIO (green color). C2C12 cells were seeded at 1x106 cells/mL with 1x105 D1
cells/mL hydrogel tube spaces. Initially, few cells could be observed in the amplified image.
After 24 hours, most of the cells showed round and spread morphology, suggesting almost
all cells attached to the hydrogel tubes. On day 4, a confluent cell monolayer was formed
on the inner surface of alginate tubes. Cells proliferate rapidly and generate a confluent
monolayer. On day 7, The cells kept expanding, multilayer cell masses were seen (Figure
5.6A, green arrows on d7). The white cell mass in the dark-field image (Figure 5.6A,
yellow arrows on d7) indicated 3D multilayer cell masses were formed. After the cells were
cultured for 14 days, the more extensive 3D white cell masses were constructed in the
hydrogel tubes (yellow arrows), and myotubes could be found (blue arrows). Alginate
hydrogel tubes were bent by the strong cell contractile force after 14 days (red arrows),
indicating the hydrogel elasticity is not enough for the myotube contraction (Figure 5.6A).
Only 10% of D1 cells were applied to avoid taking over the culture. Fluorescent images
on day 0 to day 7 suggested D1 cells did not have a growth advantage over C2C12 cells
(Figure 5.6B). Cells exhibited healthy morphologies when they were harvested and
digested into single cells (Figure 5.6C). Immunostaining on myofiber (MF20) showed the
existence of myotubes, indicating D1 cells did not inhibit the spontaneous C2C12 cell
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differentiation (Figure 5.6C).
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Figure 5.6. C2C12 and D1 cells co-culture in AlgTubes. (A) Phase or dark-field pictures of cells in
AlgTubes on different days. (B) Phase and fluorescent images of cells in AlgTubes. Green: D1 cells. (C)
Cells were released from the tubes on day 19 and stained with MF20 and PI. Green arrows: multilayer cell
masses; yellow arrows: 3D white cells mass; blue arrows: myotubes; red arrows: bent tubes.

We evaluated if C2C12 cells could be differentiated when D1 cells were presented.
After co-cultured for 6 days, the medium was changed to a differentiation medium. The
differentiation was similar to monoculture (Figure 5.7). Cells maintained proliferation to
form 3D cell masses, and myotubes could be seen after six days of differentiation (Figure
5.7A, blue arrows). The immunostaining shows that most cells were MF20 positive,
indicating D1 cells did not inhibit C2C12 differentiation (Figure 5.7B). Based on images,
D1 cells did not significantly change the cell culture. However, cell counting showed that
co-culture improved the volumetric yield, especially under differentiation conditions
(Figure 5.8). In expansion medium, C2C12 cells reached ~6.4x107, and ~1.1x108 cells/mL
hydrogel tubes tube space on day 10 and 19, respectively (Figure 5.3B). D1 co-culturing
improved the yield to ~1.3x108 cells/ml hydrogel tubes. In the differentiation medium,
~1.2x108 cells/ml hydrogel tubes were achieved on day 19. D1 co-culturing increased the
yield to ~1.6x108 cells/ml hydrogel tubes (Figure 5.8). The Countless II cell counter was
applied in this counting process. The actual yields should be higher than the numbers listed
above since the cell counter excluded the large cell aggregates, which were commonly
observed on day 19.
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Figure 5.7. C2C12 and co-culture and differentiation in AlgTubes. C2C12 and D1 cells were cultured for 7
days in alginate tube before differentiation. (A) Phase or dark-field pictures of C2C12 differentiation in
AlgTubes on different days. (B) cell fiber cryosections were immunostained with MF20, MyoD and PAX7.
Blue arrows: Myotubes.
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Figure 5.8. Quantifications of C2C12 cultured under different conditions in AlgTubes on day 19.

QM7 expansion in AlgTubes
We then cultured myoblasts from a second species quail (QM7) in AlgTubes for 18
days (Figure 5.9). After 24 hours, most cells attached to the hydrogel tube wall and
exhibited fibroblast-like morphology. The day 3 images showed cells expanded
significantly. However, a confluent monolayer had yet formed. On day 6, multilayer cell
masses were seen (Figure 5.9A, green arrows). The dark-field image also had white cell
mass (Figure 5.9A, yellow arrows), indicating 3D multilayer cell masses. However, some
hydrogel inner surfaces were still not covered with cells (Figure 5.9A, blue arrow). This
was different from C2C12 cells (Figure 5.2A), which formed a confluent monolayer before
forming 3D cell masses. This data indicated quail cells might have stronger cell-to-cell
interactions and weaker cell-to-hydrogel matrix interactions than the C2C12 cells. Most
likely, quail cells express fewer integrins for the RGD ligands than C2C12 cells. We expect
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that increasing the RGD concentration or increasing the hydrogel tube modulus will
enhance cell adhesion and enhance cell culture outcomes. After 9 days, the dark-field
images showed extensive 3D white cell masses (Figure 5.9A, yellow arrows). However,
the cells started to form dense aggregates around 12 days and became more evident on day
15 and day 18 (Figure 5.9A, red arrows).
The cell quantification showed that the yields of QM7 cells cultured for 11 days
and 18 days were both ~1.2 x 108 cell/mL (Figure 5.9B). The released day 11 cells had
healthy morphologies. Live/dead cell staining showed that most cells were alive on day 11
with a few dead cells found (Figure 5.10A). The Live/Dead cell staining for the whole cell
fiber indicates that the dead cells were mainly inside the multilayers, especially the dense
area (Figure 5.10A, red arrows). The released day 18 cells showed more cell death by
Live/Dead cell staining (Figure 5.10B). There were more and larger aggregates in the tubes,
and the dead cells were mainly inside the aggregates (Figure 5.10B, red arrows). Because
cell death significantly increased from day 11 to day 18, the yields were very similar even
cells continued to grow from day 11 to day 18 (Figure 5.9B).
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Figure 5.9. QM7 expansion in AlgTubes. (A) Phase or dark-field pictures of QM7 cells in AlgTubes on
different days. (B) QM7 quantification on day 0, day 11 and day 18. Green arrows: multilayer cell masses;
yellow arrows: 3D white cells mass; red arrows: dense aggregates.
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Figure 5.10. Live/Dead cell staining of QM7 cultured in AlgTubes on day 11 (A) and day 18 (B).
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Quail cell differentiation in AlgTubes
Before initiating differentiation, quail cells were first expanded for 6 days and
reached 80-90% confluence in AlgTubes (Figure 5.11). Cells continued to proliferate and
formed 3D cell masses in the differentiation process. Myotubes could be seen after 3 days
of differentiation (Figure 5.11A, blue arrows). Live/Dead cell staining indicates a slight
decrease of dead cells than QM7 expansion only, but still significant dead cells. The dead
cells were also mainly inside the large and dark aggregates (Figure 5.11B, red arrows).
Immunostaining confirmed the formation of myotubes, which were aligned along the
hydrogel tubes. The myotubes also expressed MyoD and PAX7, indicating the muscle
differentiation of QM7 cells was promoted (Figure 5.11C). Compared to C2C12 cells,
QM7 had more dead cells on day 18 both in expansion and differentiation. This could be
due to the less adhesion to the hydrogel tubes and QM7 cells formed aggregates after being
cultured for 11 days. Results in Figure 5.1 and Figure 5.8 show C2C12 and QM7 cells
behaved differently in AlgTubes. C2C12 cells formed a confluent monolayer before
forming 3D structures, while quail cells tended to form 3D cell aggregated. We asked if
the AlgTubes caused the difference or it was the cells’ intrinsic difference. We cultured
and differentiated C2C12 and QM7 using the traditional 2D cell culture dishes (Figure
5.12 and 5.13). On day 5, both cells formed myotubes. On day 11, more myotubes were
formed for C2C12 cells, while quail myotubes aggregated. The results show that AlgTubes
did not alter cells’ intrinsic programs.
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Figure 5.11. QM7 differentiation in AlgTubes. QM7 were first expanded for 6 days in AlgTubes before
initiating differentiation. (A) Phase or dark-field pictures of QM7 differentiation in AlgTubes on different
days. Day 18 cells were harvested for live/dead staining (B) and fixed for MF20, MyoD and PAX7
immunostaining (C). Blue arrows: Myotubes; red arrows: dead cells in aggregates.
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Figure 5.12. C2C12 differentiation in 2D culture. Differentiation started on day 2. (A) Phase images of 2D
culture. (B) Immunostaining of MF20.
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Figure 5.13. QM7 differentiation in 2D culture. Differentiation started on day 3. (A) Phase images of 2D
culture. (B) Immunostaining of MF20.
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QM7 and D1 cell co-culture
Similar to C2C12, we did the QM7 l and D1 cell co-culture. D1 cells did not alter
the cell culture outcome significantly. For expansion, cells attached the inner surface of the
hydrogel tubes after 24 hours without apparent cell death. Cells did not reach a confluent
monolayer until multilayer cell masses were observed on day 6 (Figure 5.14A, green
arrows). The dark-field images showed 3D multilayer cell masses from day 6 (Figure
5.14A, yellow arrows),). Cells started to form dense aggregates around 12 days and became
more obvious on day 15 and day 18 (Figure 5.14A, red arrows). Live/dead staining still
showed significant cell death on day 18 (Figure 5.14B). Like QM7 single culture, dead
cells were mainly in the large and dense dark aggregates (Figure 5.14B, red arrows). Thus,
D1 co-culture did not cause significant changes on QM7 and did not increase QM7 survival
in the expansion medium.
We also evaluated if the D1 cells would increase the QM7 yield or differentiation
in AlgTubes in the differentiation medium. QM7 and D1 cells were first expanded for 6
days in AlgTubes before initiating differentiation. QM7 cells continued to proliferate and
formed white cell masses. Myotubes were formed after 6 days of differentiation (Figure
5.15A). However, significantly less cell death than the monoculture and co-culture in
expansion medium was detected on day 18 (Figure 5.15B). The MF20 immunostaining
confirmed the formation of myotubes. Most cells were MF20 positive(Figure 5.15C). Thus,
D1 co-culture significantly increased QM7 survival in the differentiation medium.
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Figure 5.14. QM7 and D1 cells expansion in AlgTubes. (A) Phase or dark-field pictures of cells in AlgTubes
on different days. (B) Live dead cell staining on day 18. Green arrows: multilayer cell masses; orange arrows:
3D white cells mass; red arrows: dense aggregates.
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Figure 5.15. QM7 and D1 cell differentiation in AlgTubes. QM7 and D1 cells were first expanded for 6 days.
(A) Phase or dark-field pictures of cells in AlgTubes on different days. Day 18 cells were harvested for
live/dead staining (B) and fixed for MF20 immunostaining (C).
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QM7 and 3T3 cell co-culture
Fibroblasts are another type of stromal cells that can boost the survival of other cell
types. We thus did co-culture experiments to evaluate if mouse 3T3 fibroblasts could boost
the growth rate and yield of QM7 in AlgTubes (Figure 5.16). Cells attached to the hydrogel
tubes after seeded in the hydrogel tubes for 24 hours. On day 6, cells started to form
multilayer cell masses before reaching a confluent monolayer (Figure 5.16A). Dense
aggregates were formed after being cultured for 12 days and continued to increase (Figure
5.16A). Live/dead staining still showed significant cell death on day 18 (Figure 5.16B).
Similar to QM7 monoculture, the dead cells were mainly in the large and dense dark
aggregates (Figure 5.16B).
Differentiation was initiated after QM7 and 3T3 were co-cultured for 6 days in
AlgTubes. QM7 cells continued to proliferate and formed white cell masses as shown in
dark-field images. Myotubes can be seen after 6 days of differentiation (Figure 5.17A,
blue arrows), while dense and dark aggregates were formed. Significant cell death in the
aggregates was still shown by Live/Dead cell staining on day 18 (Figure 5.17B). Cells
were harvested and fixed for immunostaining. Most cells were MF20 positive, which
confirmed the formation of myotubes. The myotubes are also expressed high percentages
of MyoD and PAX7 (Figure 5.17C). Thus, 3T3 co-culture did not cause significant
changes on QM7.
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Figure 5.16. QM7 and 3T3 cells expansion in Alg-RGD-Tubes. (A) Phase or dark-field pictures of cells in
AlgTubes on different days. (B) Live dead cell staining on day 18.
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Figure 5.17. QM7 and 3T3 cells differentiation in AlgTubes. QM7 and D1 cells were first expanded for 6
days in AlgTubes before initiating differentiation. (A) Phase or dark-field pictures of cells in AlgTubes on
different days. Day 18 cells were harvested for live/dead staining (B) and fixed for MF20 immunostaining
(C).
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Quantification of QM7 monoculture and co-culture
To quantify the QM7 growth rate further, we harvested and digested the cells in the
hydrogel tubes on day 18 and then used the Countless II cell counter to count the cells
(Figure 5.18). We achieved a final yield of about 1.2 x108 cells/mL hydrogel tubes on day
18 without differentiation and reached about 1.3x108 cells/mL hydrogel tubes on day 18
with differentiation. When co-cultured with D1 cells, the yield was similar to QM7
monoculture without differentiation, which is ~1.15 x108 cells/mL. However, D1 cell coculture and differentiation significantly increased the yield to ~1.9 x108 cells/mL, which
corresponds to the Live/Dead cell staining. When QM7 cells were co-cultured with D1
cells in the differentiation medium, significantly fewer dead cells were detected (Figure
5.15B). When QM7 cells were co-cultured with 3T3 cells, the expansion yield improved
to ~1.45 x108 cells/mL, though there is no statistical difference. Moreover, differentiation
did not change the yield, which is also ~1.1 x108 cells/mL. Overall, the QM7 cells in the
AlgTubes can achieve a final yield of more than 1.1 x108 cells/mL. If we want less cell
death, we can culture the QM7 cells only for 11 days per passage before large and dense
aggregates are formed. If a long-term culture with a higher yield is expected, the alginate
tubes could be modified with higher RGD concentration or higher stiffness.
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Figure 5.18. Quantifications of QM7 cultured under different conditions in AlgTubes on day 19.

X9 expansion in Alg Tubes
Adipocytes are another main type of cell in meat. Thus, we used the mouse preadipocyte X9 to examine if our system could produce a large number of pre-adipocytes or
adipocytes (Figure 5.19). X9 cells were seeded with a low density (1 x106 cells/mL). After
24 hours, most cells were attached to the hydrogel tube wall with no cell death. Unlike
C2C12 and QM7, X9 cells expanded very slowly. The cell numbers in day 3 images were
very similar to day 1. A confluent monolayer had yet formed even after 10 days. After 13
days, most areas were confluent, and few multilayer cell masses were seen (Figure 5.19A,
green arrows). However, even after 19 days of culture, most hydrogel tubes’ inner surface
areas were still a single layer of X9 cells, and no large cell mass was seen (Figure 5.19A).
The yield of X9 cells was 3.5 x106 cells/mL on day 19(Figure 5.19B). The Live/Dead cell
staining on day 19 showed most cells were live cells with few dead cells were detected
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(Figure 5.19C). Although X9 cells expanded slowly in AlgTubes, the cells did grow in the
hydrogel tubes and without significant cell death.

Figure 5.19. X9 cells expansion in AlgTubes. (A) Phase or dark-field pictures of X9 cells on different days.
(B) Cell quantification in alginate tubes on day 0 and day 19. (C) Live/Dead cell staining on day 19.
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Discussion and Conclusion
Large numbers of cells are needed for meat production. Additionally, the cost of
cell production should be low so the final meat can be commercially viable. Current cell
culture methods cannot meet this need. Due to its enormous success in culturing Chinese
hamster ovary cells for producing protein therapeutics, 3D suspension culturing (e.g., a
stirred-tank bioreactor), which suspends and cultures cells in an agitated medium, are being
studied to scale up mammalian cell production19,20. However, several critical problems
limit its success21–25. First, most mammalian cells have strong cell-cell interactions26,27,
making them aggregate to form large cell agglomerates (i.e., agglomeration)28–30. The mass
transport to cells located at the center of large agglomerates (e.g., >400 µm diameter, the
diffusion limit in tissue) becomes insufficient, leading to slow cell growth, apoptosis, and
uncontrolled differentiation30,31. Second, the agitation generates hydrodynamic conditions
(e.g., the medium flow direction, velocity, shear force, and chemical environment) that
vary spatially and temporally, resulting in locations with critical shear stress (e.g., near the
vessel wall) that induce large cell death28–30. We24,25 and others21–23 show cells typically
expand less than 10-fold per passage to yield less than 5x106 cells/mL in 3D suspension
culturing. These cells occupy <1% of the culture volume25.
Third, the hydrodynamic conditions are highly variable and sensitive to many
factors, including bioreactor design (e.g., impeller geometry, size, and position; vessel
geometry and size; positions of probes for pH, temperature, and oxygen), medium viscosity,
and agitation rate30,32. They are currently not well understood and are hard to control28–30,32.
Additionally, different cell types respond to hydrodynamic conditions differently28–30.
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These result in significant culture variations between batches and cell lines and difficulty
in scaling up. For instance, in recent studies to make hPSC-CMs from two hPSC lines in
suspension culturing, the yield varied from 40 million to 125 million cells. The product
purity varied from 28% to 88% in different batches (100 mL culture volume)33,34. When
the culture was scaled from ~100 mL to ~1,000 mL, the yield and differentiation efficiency
was significantly altered, and re-optimization was required33,34. These indicate the
challenge of further scaling up (e.g., hundreds of liters) since optimizing multiple factors
in a large volume is costly.
We and others have cultured cells in hydrogels with the intention of using hydrogels
as physical barriers to eliminate cell agglomeration and shear stress35–38, but cells have
slow growth in most hydrogels. We speculate it is due to several factors: (1) the hydrogels
hinder the initial cellular interactions required for their survival after cell passaging, and
(2) cells must degrade or deform the scaffold to create spaces for the new cells.
Significantly, we found a very soft thermoreversible hydrogel that enabled high yield
(~2.0x107 cells/mL)24,25,39–41. However, this hydrogel is unsuitable for large-scale cell
production because the material is expensive and highly variable between batches.
In this study, we showed that our AlgTubes could support both expansion and
differentiation of mouse and quail myoblasts. The yield reached ~1.5x108 cells/mL. To our
best knowledge, this is the first time to achieve a volumetric yield above 100 million per
ml culture volume. More importantly, the AlgTubes system is scalable. We believe this
system is appropriate for meat production and will significantly impact this emerging field.
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CHAPTER 6.

CREATING A CELL-FRIENDLY MICROENVIRONMENT

TO ENHANCE THE CELL CULTURE EFFICIENCY
The need for more efficient cell culture technologies
A number of cellular therapeutics have been approved and hundreds of clinical
trials are on-going. Cells will be a major type of medicine in the future. Human cells are
also needed in large amounts for disease modeling, drug discovery and tissue engineering.
To achieve the full potential of cellular therapeutics, we must be able to cost-effectively
and reproducibly manufacture cells at large scales and with high quality1. Cells can be
prepared and used as off-the-shelf products (i.e. allogenic cells). Allogenic cells have
relatively low production cost, high quality control, and are available when patients need
them. The commercial success of allogenic cellular therapeutics relies on a technology that
can culture massive numbers of cells per batch (e.g. 1012 to 1013 cells per batch)2–4.
Alternatively, autologous cells can be prepared for personalized treatment. Autologous
cells have minimal immune rejection but their production cost is high and the production
variation between patients is significant5–10. The commercial success of autologous cells
requires a technology that can consistently culture cells for thousands of patients in parallel
with affordable cost11. Currently, robust and cost-effective culture of high-quality allogenic
or autologous cells in large scales is still very challenging1,12,13. Significant problems
associated with the large-scale cell culture including the low cell yield, low scalability,
high cost, large culture variation, and significant genetic and phenotypic changes. A
healthy growth of cell therapy industry needs innovations and breakthroughs on cell culture
technologies. This article will use human pluripotent stem cells (hPSCs) as examples to
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show the critical need of creating a cell-friendly microenvironment during large-scale cell
culture. Though different cell types require different microenvironments, the principles
and technologies discussed in this article are suitable for other cell types.
Current cell culture technologies cannot provide a cell-friendly microenvironment
In vivo, most of our cells reside in a 3D microenvironment with abundant cell-tocell, cell-to-matrix interactions, local growth factors, autocrine and paracrine signaling,
which collectively regulate the cell survival, growth, differentiation and functions (Figure
6.1). In most of human tissues, the cellular microenvironment is soft and elastic. There are
dense blood vessels to efficiently transport oxygen, nutrients, growth factors and metabolic
wastes. The diffusion limit in human tissue is typically less than a few hundreds of
micrometers. In most of human tissues, cells experience minimal hydrodynamic stresses.
The cellular microenvironments of current cell culture methods are very different from this
in vivo 3D microenvironment:

Figure 6.1. The 3D cellular microenvironment in vivo.
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The two-dimensional (2D) cell culture method
Culturing cells on 2D surfaces is widely practiced. However, a 2D environment is
very different from cells’ in vivo 3D environment (Figure 6.2). In 2D culture, cells are
polarized and the cell-to-cell and cell-to-matrix interactions and local growth factors are
considerably reduced. The apical surfaces of cells are free while the bottom surfaces are
attached to a substrate, which is typically very stiff. To adapt to this physiologicallyirrelevant microenvironment, cells change their genetics and phenotypes14–17. Cells that
adapt well proliferate and gradually take over the culture. For instance, research shows 34%
hPSC lines that have been cultured in 2D culture for long-term have large chromosomal
abnormalities14–19. Additionally, 2D culturing has low yield and is labor-, space-, and
reagent-consuming. 2D culturing is generally considered suitable for preparing low-scale
cells20.

Figure 6.2. The two-dimensional (2D) cell culture method
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The three-dimensional (3D) suspension culture method
Due to its enormous success for culturing protein-producing cells (e.g. Chinese
hamster ovary or CHO cells), 3D suspension culturing (e.g., in a stirred-tank bioreactor),
which suspends and cultures cells in an agitated medium, has been extensively studied to
scale up the cell cutlure21,22. However, there are still several critical problems with the
cellular microenvironment of this system (Figure 6.3)2–4,23,24. First, most human cells have
strong cell-cell interactions25,26 that make them aggregate to form large agglomerates27–29.
The mass transport to cells located at the center of agglomerates larger than the diffusion
limit becomes insufficient, leading to slow cell growth, apoptosis, and uncontrolled
differentiation29,30. Second, the agitation generates hydrodynamic conditions (e.g., the
medium flow direction, velocity, shear force, and chemical environment) that vary spatially
and temporally, resulting in locations with critical hydrodynamic stresses (e.g., near the
vessel wall) that induce large cell death. These factors lead to low cell expansion per
passage and low volumetric yield27–29. For instance, hPSCs typically expand less than 10
folds every passage (about 4 to 10 days) to yield ~2.0x to 5x106 cells/mL in 3D suspension
culturing2–4,23,24 These cells occupy <1% of the culture volume24. Third, the hydrodynamic
conditions are highly variable and sensitive to many factors, including the bioreactor design
(e.g., the impeller geometry, size, and position; vessel geometry and size; positions of
probes for pH, temperature, and oxygen), medium viscosity, and agitation rate29,31.
Reproducibly and precisely controlling the hydrodynamic conditions is challenging.
Additionally, different cell types respond to hydrodynamic conditions differently27–29.
These contribute to the large culture variations between batches and cell lines. For instance,
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in recent studies to make cardiomyocytes from hPSCs in suspension culturing, the yield
varied from 40 million to 125 million cells and the product purity varied from 28% to 88%
in different batches (100 mL culture volume)32,33. When the culture was scaled from ~100
mL to ~1,000 mL, the yield and differentiation efficiency were significantly altered,
requiring re-optimization32,33. These indicate the challenge of further scaling up (e.g.,
hundreds of liters), since optimizing multiple factors in a large volume is costly.
Additionally, the shear stress and hydrodynamic variations become more severe at large
scales, leading to more cell death and production variations27–29,31. Moreover, aeration (i.e.,
bubbling the medium with oxygen), which is required to meet the oxygen supply needs of
large cultures, also causes significant cell death34.
Cells can also be cultured on microcarriers suspended in a bioreactor35. This method
also has the cell aggregation, shear-force induced cell death, hydrodynamic variation and
scale up problems. The volumetric yield is also low. Using microcarriers also has some of
the problems associated with 2D culture, such as the cell polarity and the stiff substrateinduced cell changes. During the harvest, detaching cells from microcarriers using enzymes
and mechanical force, and separating the dissociated cells from microcarriers at large scale
re both very challenging.
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Figure 6.3. The three-dimensional (3D) suspension culture method
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The hollow fiber cell culture method
Polymer hollow fibers have been used for culturing cells36–38. This method mimics
the in vivo circulation and can generate high volumetric yield. However, it also has some
critical problems with the microenvironment. The dense cells consume oxygen and
nutrients at a fast rate, thus the composition of culture medium along the hollow fibers (e.g.
at the entrance and exit of hollow fibers) are expected to be different. Consequently, cells
at different locations face very different microenvironment. Additionally, cells adhere to
the fibers, and harvesting cells typically takes tens of minutes enzymatic treatment to
detach cells from the fibers. This treatment can lead to large cell death.
Culture cells in hydrogels
Scientists have cultured cells in hydrogels with the intention of using hydrogel
scaffolds to eliminate cell agglomeration and hydrodynamic stresses39–42. However, cells
typically have moderate growth rate and volumetric yield in hydrogels23,24,43–45. First, the
scaffolds prevent the initial cellular interactions required for the survival of some cell types
after cell passaging. Second, the scaffolds constrain cells. Cells have to degrade or deform
the scaffolds to create spaces for the new born cells. In summary, current cell culture
methods have not been designed to provide cells a well-controlled and friendly
microenvironment, and consequently, the cell culture efficiency is not satisfactory.
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Creating a cell-friendly microenvironment can significantly improve the culture
outcome
Recently, researchers developed scalable and dissolvable micro-bioreactors that
can create a cell-friendly and 3D microenvironment for cell cutlure46–52. Specifically, cells
are cultured in microscale hollow tubes made with alginate hydrogel (i.e., AlgTubes)46–52.
To process hydrogel tubes, a cell solution and an alginate solution are pumped into the
central channel and side channel of a micro-extruder, respectively, to form coaxial coreshell flows that are extruded into a CaCl2 buffer. The shell alginate flow is instantly
crosslinked by Ca2+ ions to generate a hydrogel tube, and cells are grown in the tube. The
tube’s diameter and shell thickness can be precisely controlled by adjusting the nozzle
diameter and the ratio of the shell and core flows. Typically, a shell thickness <40 µm and
tube diameter <400 µm can ensure efficient mass transport and are appropriate for culturing
cells. The tubes can be dissolved with the cell-compatible ethylenediaminetetraacetic acid
solution (EDTA, 0.5 mM) in five minutes at room temperature to harvest the cells for the
next passage or applications.
This system is designed to provide cells a friendly microenvironment (Figure 6.4
and 6.5). First, oxygen, nutrients and macromolecules (with Mw up to 700 kDa) can freely
and quickly diffuse through the hydrogel shell. The hydrogel tubes direct cell expansion
axially, while confining the radial diameter of cell masses within the diffusion limit (~400
μm) to ensure efficient mass transport. Second, the hydrogel tubes also isolate
hydrodynamic stresses from cells, and lastly, the tubes provide free and uniform 3D
microspaces that allow cells to interact with each other and grow. The system is also
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designed to be simple, scalable, low-cost and commercially-viable: i) Alginate hydrogels
can be quickly processed in large scales with a multi-nozzle extruder46–52; ii) They can be
quickly dissolved with the cell-compatible EDTA solution to release the product without
harming cells; iii) The tubes are mechanically and chemically stable that allow culturing
cells for long term (e.g. up to a few months) and at large scales; and iv) alginates are
affordable and available in large quantities, and they have been used in clinics and have no
cellular toxicity.
The cell-friendly microenvironment brings enormous improvements in culture
efficiency including cell viability, growth rate, yield, genetic and phenotype stability,
culture consistence and scalability (scale out and up)46–52. For instance, hPSCs expand
~1000-fold per 9 days per passage to yield ~5.0x108 cells per milliliter of hydrogel tubes.
For comparison, hPSCs typically expand less than 10-fold per passage to yield less than
5x106 cells/mL in 3D suspension culture. Cells in AlgTubes have less DNA damage and
phenotype changes: factors that correlate with higher product safety and potency. This
method has been demonstrated for hPSCs expansion, differentiation and reprograming, as
well as for expanding T cells and adult stem cells, all with extremely high efficiency46–52.
The high yield and expansion/passage make it possible to produce clinically
relevant numbers of cells (e.g., 1x1010) for each patient from small amounts of starting
cells (e.g., 1x107) with less than 20 mL hydrogel tubes contained in a small, disposable
bioreactor (e.g. a 50-mL conical tube) without passaging48,50. For instance, to make
personalized dopaminergic (DA) neuron progenitors48,

reprogramming factors were

delivered to fibroblasts through electroporation and cells were processed into the hydrogel

166

tubes into a conical tube. Cells were reprogrammed for 20 days, expanded for 10 days, and
differentiated into DA progenitors for 11 days in the sealed conical tube. On day 41, 0.5
mM EDTA was infused to dissolve hydrogel tubes. Few cells died during production. Cells
survived well and matured into TH+ DA neurons in vivo. This all-in-one-tube device, if
fully developed and automated, can have a significant impact on scaling out the production
of autologous cells for personalized cell therapy.
The high expansion/passage and yield also have high impact on scaling up the cell
production46. For instance, mathematical modeling shows producing 1.5x1014 hPSCs (from
2x108 hPSC seeds) with stirred-tank bioreactors requires ~104,811 liters of total bioreactor
volume, 11 passaging operations, and 48 days, which is technically and economically
challenging. The same production can be done with about 320 liters of AlgTubes in 20
days and 1 passaging operation. The reductions in culture volume, time, and passaging
makes the production technically and economically feasible.

Figure 6.4. The cell-friendly microenvironment of alginate hydrogel tubes.
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Day 8

Day 12

Day 10

Day 14

Figure 6.5. The monodispersed cell mass in one alginate hydrogel tube suspended in a 6-well plate
5
on day 8, 10, 12 and 14. Cells were seeded as 3x10 cells/mL
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Summary
There is a critical need to develop efficient cell culture technologies to achieve the
full potential of cellular therapeutics. Academia and industry are currently focusing on
developing modular, disposable and closed bioreactors; automating the cell culture;
integrating process analysis and control and artificial intelligence; and scaling out and
scaling up the 3D suspension culture system1. These efforts are significant since they can
change the current manual manufacturing to automated manufacturing. However, these
efforts may not sufficient to fully address the large-scale cell culture challenge since they
are not enough to create a cell-friendly microenvironment. The AlgTubes system shows
improving the cellular microenvironment has enormous impact on the culture outcome. Its
success indicates the academia and industry should put more efforts on creating a cellfriendly microenvironment during the cell manufacturing.

169

Reference
1.

Achieving large-scale, cost-effective, reproducible manufacturing of high-quality
cells. A Technology Roadmap to 2025. Consortium, Natl. Cell Manuf. (2016).

2.

Denning, C. et al. Cardiomyocytes from human pluripotent stem cells: From
laboratory curiosity to industrial biomedical platform. Biochim. Biophys. Acta Mol. Cell Res. 1863, 1728–1748 (2016).

3.

Kempf, H., Andree, B. & Zweigerdt, R. Large-scale production of human
pluripotent stem cell derived cardiomyocytes. Adv. Drug Deliv. Rev. 96, 18–30
(2016).

4.

Hartman, M. E., Dai, D. & La, M. A. Human pluripotent stem cells: prospects and
challenges as a source of cardiomyocytes for in vitro modeling and cell-based
cardiac repair. Adv. Drug Deliv. Rev. 96, 3–17 (2016).

5.

Wang, X. & Rivière, I. Clinical manufacturing of CAR T cells: Foundation of a
promising therapy. Mol. Ther. - Oncolytics 3, 1–7 (2016).

6.

Maier, D. Challenges & opportunities for manufacturing autologous cellular
therapies such as CAR-T cells. Cell Gene Ther. Insights 3, 261–265 (2017).

7.

Sharpe, M. & Mount, N. Genetically modified T cells in cancer therapy:
opportunities and challenges. Dis. Model. Mech. 8, 337–350 (2015).

8.

Levine, B. Progress and challenges in the manufacturing of CAR-T cell therapy.

170

Cell Gene Ther. Insights 3, 255–260 (2017).
9.

Hartmann, J., Schüßler‐Lenz, M., Bondanza, A. & Buchholz, C. J. Clinical
development of CAR T cells—challenges and opportunities in translating
innovative treatment concepts. EMBO Mol. Med. 9, 1183–1197 (2017).

10.

Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR
T cell therapy. Mol. Ther. - Methods Clin. Dev. 4, 92–101 (2017).

11.

Trainor, N., Pietak, A. & Smith, T. Rethinking clinical delivery of adult stem cell
therapies. Nat. Biotechnol. 32, 729–735 (2014).

12.

Baum, E., Littman, N., Ruffin, M., Ward, S. & Aschheim, K. Key tools and
technology hurdles in advancing stem-cell therapies. California Institute for
Regenerative Medicine, Alliance for Regenerative Medicine Catapult, Cell
Therapy. (2013).

13.

National science and technology council: Advance manufacturing: a snapshot of
priority technology areas across the federal government subcommittee for
advanced manufacturing. (2016).

14.

Lund, R. J., Närvä, E. & Lahesmaa, R. Genetic and epigenetic stability of human
pluripotent stem cells. Nat. Rev. Genet. 13, 732–744 (2012).

15.

Peterson, S. E., Garitaonandia, I. & Loring, J. F. The tumorigenic potential of
pluripotent stem cells: What can we do to minimize it? BioEssays 38, S86–S95
(2016).

171

16.

Garitaonandia, I. et al. Increased risk of genetic and epigenetic instability in human
embryonic stem cells associated with specific culture conditions. PLoS One 10,
e0118307 (2015).

17.

Weissbein, U., Benvenisty, N. & Ben-david, U. Genome maintenance in
pluripotent stem cells. J. Cell Biol. 204, 153–163 (2014).

18.

Peterson, S. E. & Loring, J. F. Genomic instability in pluripotent stem cells:
implications for clinical applications. J. Biol. Chem. 289, 4578–4584 (2014).

19.

Amps, K. et al. Screening ethnically diverse human embryonic stem cells
identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat
Biotechnol. 29, 1132–1144 (2011).

20.

Brandwein, H., Rowley, J., Abraham, E., Campbell, A. & Oh, S. Meeting Lot-Size
Challenges of Manufacturing Adherent Cells for Therapy. Bioprocess Int. 10, 16–
22 (2012).

21.

Polak, J. M. & Mantalaris, S. Stem cells bioprocessing: an important milestone to
move regenerative medicine research into the clinical arena. Pediatr. Res. 63, 461–
466 (2008).

22.

Serra, M., Brito, C., Correia, C. & Alves, P. M. Process engineering of human
pluripotent stem cells for clinical application. Trends Biotechnol. 30, 350–358
(2012).

23.

Lei, Y., Jeong, D., Xiao, J. & Schaffer, D. V. Developing Defined and Scalable 3D

172

Culture Systems for Culturing Human Pluripotent Stem Cells at High Densities.
Cell Mol Bioeng 7, 172–183 (2014).
24.

Lei, Y. & Schaffer, D. V. A fully defined and scalable 3D culture system for
human pluripotent stem cell expansion and differentiation. Proc. Natl. Acad. Sci.
U. S. A. 110, E5039-48 (2013).

25.

Chen, K. G. et al. Developmental insights from early mammalian embryos and
core signaling pathways that influence human pluripotent cell growth and
differentiation. Stem Cell Res. 12, 610–621 (2014).

26.

Chen, K. G., Mallon, B. S., McKay, R. D. G. & Robey, P. G. Human pluripotent
stem cell culture: considerations for maintenance, expansion, and therapeutics.
Cell Stem Cell 14, 13–26 (2014).

27.

Kinney, M. A., Sargent, C. Y. & Mcdevitt, T. C. The multiparametric effects of
hydrodynamic environments on stem cell culture. Tissue Eng. Part B 17, 249–262
(2011).

28.

Fridley, K. M., Kinney, M. A. & McDevitt, T. C. Hydrodynamic modulation of
pluripotent stem cells. Stem Cell Res. Ther. 3, 45 (2012).

29.

Kropp, C., Massai, D. & Zweigerdt, R. Progress and challenges in large-scale
expansion of human pluripotent stem cells. Process Biochem. 59, 244–254 (2017).

30.

Hajdu, Z. et al. Tissue spheroid fusion-based in vitro screening assays for analysis
of tissue maturation. J. Tissue Eng. Regen. Med. 4, 659–664 (2010).

173

31.

Ismadi, M., Gupta, P., Fouras, A., Verma, P. & Jadhav, S. Flow characterization of
a spinner flask for induced pluripotent stem cell culture application. PLoS One 9,
e106493 (2014).

32.

Jara-avaca, M. et al. Controlling expansion and cardiomyogenic differentiation of
human pluripotent stem cells in scalable suspension culture. Stem cell reports 3,
1132–1146 (2014).

33.

Chen, V. C. et al. Development of a scalable suspension culture for cardiac
differentiation from human pluripotent stem cells. Stem Cell Res. 15, 365–375
(2015).

34.

Hu, W., Berdugo, C. & Chalmers, J. J. The potential of hydrodynamic damage to
animal cells of industrial relevance: Current understanding. Cytotechnology 63,
445–460 (2011).

35.

Jossen, V., van den Bos, C., Eibl, R. & Eibl, D. Manufacturing human
mesenchymal stem cells at clinical scale : process and regulatory challenges. Appl.
Microbiol. Biotechnol. 1–14 (2018).

36.

Gerlach, J. C. et al. Interwoven four-compartment capillary membrane technology
for three-dimensional perfusion with decentralized mass exchange to scale up
embryonic stem cell culture. Cells Tissues Organs 192, 39–49 (2010).

37.

Knöspel, F., Freyer, N., Stecklum, M., Jörg C, G. & Zeilinger, K. Periodic
harvesting of embryonic stem cells from a hollow-fiber membrane based four-

174

compartment bioreactor. Biotechnol. Prog. 32, 141–151 (2016).
38.

Roberts, I. et al. Scale-up of human embryonic stem cell culture using a hollow
fibre bioreactor. Biotechnol. Lett. 34, 2307–2315 (2012).

39.

Serra, M. et al. Microencapsulation technology: a powerful tool for integrating
expansion and cryopreservation of human embryonic stem cells. PLoS One 6,
e23212 (2011).

40.

Chayosumrit, M., Tuch, B. & Sidhu, K. Alginate microcapsule for propagation and
directed differentiation of hESCs to definitive endoderm. Biomaterials 31, 505–
514 (2010).

41.

Stenberg, J. et al. Sustained embryoid body formation and culture in a nonlaborious three dimensional culture system for human embryonic stem cells.
Cytotechnology 63, 227–237 (2011).

42.

Gerecht, S. et al. Hyaluronic acid hydrogel for controlled self-renewal and
differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 104,
11298–11303 (2007).

43.

Lin, H., Li, Q. & Lei, Y. Three-dimensional tissues using human pluripotent stem
cell spheroids as biofabrication building blocks. Biofabrication 9, 025007 (2017).

44.

Lin, H., Li, Q. & Lei, Y. An Integrated Miniature Bioprocessing for Personalized
Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural
Stem Cells. Sci. Rep. 7, 40191 (2017).

175

45.

Li, Q. et al. Scalable production of glioblastoma tumor-initiating cells in 3
dimension thermoreversible hydrogels. Sci. Rep. 6, 31915 (2016).

46.

Li, Q. et al. Scalable and physiologically relevant microenvironments for human
pluripotent stem cell expansion and differentiation. Biofabrication 10, 025006
(2018).

47.

Lin, H. et al. Hydrogel-Based Bioprocess for Scalable Manufacturing of Human
Pluripotent Stem Cell-Derived Neural Stem Cells. ACS Appl. Mater. Interfaces 10,
29238–29250 (2018).

48.

Lin, H. et al. Integrated generation of induced pluripotent stem cells in a low-cost
device. Biomaterials 189, 23–36 (2019).

49.

Li, Q. et al. Scalable culturing of primary human glioblastoma tumor-initiating
cells with a cell-friendly culture system. Sci. Rep. 8, 3531 (2018).

50.

Lin, H. et al. Automated expansion of primary human T cells in scalable and cellfriendly hydrogel microtubes for adoptive immunotherapy. Adv. Healthc. Mater.
e1701297 (2018).

51.

Lin, H. et al. Manufacturing human pluripotent stem cell derived endothelial cells
in scalable and cell-friendly microenvironments. Biomater. Sci. 373–388 (2019).

52.

Lin, H. et al. Engineered Microenvironment for Manufacturing Human Pluripotent
Stem Cell-Derived Vascular Smooth Muscle Cells. Stem Cell Reports 12, (2019).

